APPENDIX 2

Preliminary Cumulative
Hazard and Dose-Response Assessment for Organophosphorus Pesticides:

Determination of Relative Potency
and Points of Departure
for Cholinesterase Inhibition

Appendix 2

Table of Contents

Abbreviations

A	Estimate of A (background cholinesterase activity)
B	Estimate of B (y-assymptote)
BMD_{10}	Benchmark dose with 10% reduction in cholinesterase activity compared to the background
BMDL	Lower 95% confidence limit on the BMD_{10}
cheI	Cholinesterase activity (usually in international units)
CL	Confidence limit
D	Number of days on study
Duplicate	Duplicate animals (i.e., satellite group, recovery animals, etc)
Duplicatewhole	Whole brain from duplicate animals
F	Female
GOF	Model goodness-of-fit
m	Estimate of absolute potency for a single cholinesterase measurement.
M	Male
main	Main study animals
MRID #	MRID study identification number
NA	Not available
RBC	Red blood cells
whole	Whole brain from the main study animals

Key to Figures in Appendix 2

Graphs of Potency versus Duration of Exposure

Y-axis	m — Absolute potency estimates for each single cholinesterase measurement
X-axis	Time (number of days)
Error bars	95% confidence intervals on absolute potency estimates
Solid vertical line	Result of regression for duration of exposure and absolute potency (i.e., rough estimate of time to steady state)
Solid horizontal line	Average absolute potency
Dotted horizontal lines	95% confidence intervals on average absolute potency



Dose-Response Curves

Y-axis	Cholinesterase measurements (usually in international units)
X-axis	Dose (mg/kg/day)
Title	MRID number followed by Number of days on Study followed by - Type of animals (i.e., main, duplicate, satellite) or brain section (i.e, whole, hippocampus, etc.)
Error bars	Standard deviations on cholinesterase measurements
Solid vertical lines	BMD_{10} and BMDL



Acephate

Acephate Table 1. - Toxicology Profile Table

ACEPHATE						
MRID #	Guideline No.	Study Type	HED Doc. No.	Dose	Guideline/ Nonguideline	Species/ Strain
40504819	82-1 (870.3100)	90-day feeding- rat (Special ChE inhibition study)	006680 012544 14258	0/0, 0.15/0.12, 0.36/0.28, 0.76/0.58, 11.48/8.90 mg/kg/day (females/males)	Nonguideline	Rat/ Sprague Dawley
45134301	82-2 (870-3200)	21-Day dermal toxicity study-rat (2000)	14210 41528	0, 20, 30, 40, 50 mg/kg/day	Nonguideline	Rat/ Sprague Dawley
45134302	82-4 (870.3465)	Subchronic Inhalation Study (2000)	14223 41528	0, 0.001064, 0.003123, 0.005550 mg/L	Nonguideline	Rat/ Sprague Dawley
44541101	82-2 (870.3200)	21-day dermal-rat	13396	0, 12, 60, 300 mg/kg/day	Guideline	Rat/ Sprague Dawley
40504818	82-4 (70.3465)	4-week inhalation- rat	12544	0 (air), 1.05, 10.8, 93.6 mg/m^3	Guideline	Rat/ Fischer 344
40645903	82-4 (80.3465)	4-week inhalation- rat	12544	0 (air), 0.187, 0.507 mg/m^3	Guideline	Rat/ Fischer 344
00084017	83-5 (70.4300)	1-year chronic feeding/ carcinogenicity study in rats	004951 012544	0, 0.25, 2.50, 35 mg/kg/day (males and females)	Guideline	Rat/ Sprague Dawley
44203304	82-7 (870.6200)	Subchronic neurotoxicity - rats	12416	0/0, 0.41/0.33, 3.95/3.31, 58.27/48.63 mg/kg/day (females/males)	Guideline	Rat/ Sprague Dawley

Acephate Table 2. - Results of Dose-Response Analysis: Exponential Parameter Estimates for Oral Route of Exposure

ACEPHATE														
Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency
Brain	F	40504819	28D -whole	11.0353177	0	0.235	0.0357	3	2	0.272	0.357	0.469	0.261	0.289	0.319
			63D - whole	11.9297238	0	0.292	0.0286	3	2						
			91D -whole	12.1515516	5.5574678	0.438	0.0904	5	0						
		00084017	49D-whole	13.5137751	2.400201	0.298	0.347	4	0	0.251	0.279	0.311			
			133D-whole	12.7183242	3.5002725	0.272	0.108	4	0						
			364D-whole	11.8528524	3.4986689	0.248	0.863	4	0						
			637D-whole	11.1111668	3.6982637	0.385	0.724	4	0						
			819D-whole	10.5814594	3.3005802	0.296	0.359	4	0						
	M	40504819	28D -whole	11.0001047	5.7158902	0.465	0.196	5	0	0.417	0.51	0.624	0.274	0.391	0.557
			63D - whole	11.9918979	6.1316902	0.598	0.84	5	0						
			91D -whole	11.8696972	5.6924649	0.445	0.729	5	0						
		00084017	49D-whole	15.2376661	3.5965661	0.229	0.373	4	0	0.264	0.305	0.353			
			133D-whole	12.1239515	3.7993466	0.273	0.924	4	0						
			364D-whole	11.669167	3.602002	0.339	0.167	4	0						
			637D-whole	11.148995	2.9985647	0.371	0.219	4	0						
			819D-whole	10.47225	3.101021	0.313	0.262	4	0						
RBC	F	44203304	21D-main	2822.376	0	0.008	0.32	4	0	0.00705	0.00885	0.0111	0.00906	0.0216	0.0517
			49D-main	3232.036	0	0.01	0.634	4	0						
			91D-main	3123.876	0	0.005	0.512	4	0						
		40504819	28D-main	632.693	0	2E-04	0.0032	3	2	0.0376	0.0546	0.0795			
			63D-main	746.2878879	0	0.05	0.303	5	0						
			91D-main	694.694368	382.8456734	0.341	0.9	5	0						
		00084017	42D-main	3246.227205	0	0.12	0.764	3	1	0.0121	0.0218	0.0392			
			49D-main	2903.036	0	0.017	0.152	4	0						
			133D-main	2680.777034	0	0.017	0.186	4	0						
			196D-main	2366.784707	867.808812	0.11	0.539	4	0						
			364D-main	2804.126	0	0.013	0.746	4	0						
			546D-main	2592.275	1325.871	0.023	0.321	4	0						
			637D-main	2616.437	0	0.013	0.323	4	0						
			728D-main	4477.24	0	0.01	0.344	4	0						
			819D-main	2240.305	0	0.016	0.0599	4	0						

Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency
RBC (con't)	M	44203304	21D-main	3510.601	1938.046	0.051	0.0901	4	0	0.00777	0.00913	0.0107	0.0094	0.0207	0.0455
			49D-main	3448.664	0	0.009	0.491	4	0						
			91D-main	3466.4	0	0.009	0.371	4	0						
		40504819	28D-main	537.7864643	212.4274688	0.207	0.682	5	0	0.0313	0.044	0.0619			
			63D-main	634.0131743	0	0.049	0.969	5	0						
			91D-main	864.8536663	0	0.035	0.708	5	0						
		00084017	42D-main	3069.669	0	0.014	0.339	4	0	0.0113	0.0236	0.0494			
			49D-main	3538.519837	1998.650504	0.252	0.735	4	0						
			133D-main	2916.833	0	0.017	0.293	4	0						
			196D-main	2366.329	640.4559	0.068	0.675	4	0						
			364D-main	2892.898	439.3582	0.021	0.08	4	0						
			546D-main	2364.556	0	0.012	0.208	4	0						
			637D-main	3098.376	0	0.01	0.523	4	0						
			728D-main	3975.846	0	0.008	0.24	4	0						
			819D-main	2391.146607	0	0.135	0.549	3	1						
Plasma	F	00084017	42D-main	3181.123022	899.9722568	0.292	0.924	4	0	0.0784	0.141	0.255	0.092	0.144	0.225
			49D-main	2868.261136	1000.372831	0.257	0.482	4	0						
			133D-main	3022.437313	1260.982722	0.109	0.878	4	0						
			196D-main	3373.551456	1287.826417	0.148	0.0998	4	0						
			364D-main	3127.19883	1282.821042	0.134	0.797	4	0						
			546D-main	2775.446318	1097.502203	0.194	0.0704	4	0						
			637D-main	2780.546	0	0.022	0.81	4	0						
			728D-main	3136.419184	1596.751804	0.174	0.664	4	0						
			819D-main	2042.728311	900.1925822	0.263	0.473	4	0						
		44203304	21D-main	2798.756459	782.624646	0.179	0.31	4	0	0.074	0.147	0.293			
			49D-main	3394.839	905.7005	0.093	0.896	4	0						
			91D-main	3689.265	935.4743	0.045	0.394	4	0						
	M	00084017	42D-main	1037.65	0	0.004	0.841	4	0	0.00723	0.0141	0.0275	0.0092	0.0447	0.217
			49D-main	1555.208	0	0.013	0.311	4	0						
			133D-main	1411.781	0	0.01	0.92	4	0						
			196D-main	1110.818	0	0.01	0.118	4	0						
			364D-main	1306.554	0	0.005	0.12	4	0						
			546D-main	1455.354714	590.3266568	0.129	0.309	4	0						
			637D-main	1627.913	0	0.009	0.059	4	0						
			728D-main	1750.228	0	0.011	0.424	4	0						
			819D-main	1427.143163	0	0.136	0.0327	3	1						
		44203304	21D-main	734.4147177	318.9359948	0.175	0.895	4	0	0.0781	0.138	0.244			
			49D-main	639.4006757	268.2689853	0.057	0.79	4	0						
			91D-main	801.4311193	323.8008839	0.098	0.0773	4	0						

Acephate Figure 1. - Potency Versus Duration of Exposure Graphs

	BRAIN	RBC	PLASMA
F			
M			

Acephate Figure 2. - Brain Female Results of Dose-Reponse Analysis: Dose-Reponse Curves for Oral Route of Exposure



44203304 21 D - MIDBRAIN



44203304 49 D - MIDBRAIN



44203304 91 D - MIDBRAIN



44203304 21 D - OLFACTORY



44203304 49 D - OLFACTORY



44203304 91 D - OLFACTORY



84017 49 D - WHOLE



84017 133 D - WHOLE



84017 364 D - WHOLE



84017 637 D - WHOLE



84017 819 D - WHOLE



Acephate Figure 3. - Brain Male Results of Dose-Reponse Analysis: Dose-Reponse Curves for Oral Route of Exposure

























Acephate Figure 4. - Plasma Female Results of Dose-Reponse Analysis: Dose-Reponse Curves for Oral Route of Exposure



Acephate Figure 5. - Plasma Male Results of Dose-Reponse Analysis: Dose-Reponse Curves for Oral Route of Exposure



Acephate Figure 6. - RBC Female Results of Dose-Reponse Analysis: Dose-Reponse Curves for Oral Route of Exposure



Acephate Figure 7. - RBC Male Results of Dose-Reponse Analysis: Dose-Reponse Curves for Oral Route of Exposure



Azinphos Methyl

Azinphos Methyl Table 1. - Toxicology Profile Table

Azinphos Methyl						
MRID #	Guideline No.	Study Type	HED Doc. No.	Dose	Guideline/ Nonguideline	Species/ Strain
43826601	82-1 (870.3100)	Subchronic oral (rat)	011898	0/0, 1.05/0.91, 3.23/2.81, 6.99/7.87 mg/kg/day (females/males)	Guideline	Rat/ Fischer 344
41119901	83-5 (870.4300)	Chronic/carcinogenicity oral– 2 years (rat)	008300	0/0, 0.31/0.25, 0.96/0.75, 3.11/2.33 mg/kg/day (females/males)	Guideline	Rat/ Wistar

Azinphos Methyl Table 2. - Results of Dose-Response Analysis: Exponential Parameter Estimates for Oral Route of Exposure

Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency
Brain	F	41119901	360D-whole	1.5937	0	0.15	3.6E-09	3	1	0.143	0.214	0.32	0.244	0.274	0.307
			720D-whole	1.3234	0	0.27	0.00047	4	1						
		43826601	88D-whole	15.738	0	0.28	0.00262	4	0	0.248	0.28	0.316			
	M	41119901	360D-whole	1.8013	0	0.02	6.7E-16	4	0	0.0191	0.0889	0.413	0.209	0.219	0.23
			720D-whole	1.4003	0	0.21	5.6E-11	4	0						
		43826601	87D-whole	16.198	0	0.22	0.00822	4	0	0.209	0.219	0.23			
RBC	F	41119901	30D-main	2729.5	0	0.16	0.00025	3	1	0.153	0.187	0.229	0.148	0.349	0.821
			90D-main	2662.5	0	0.12	3.5E-13	4	0						
			180D-main	2775	0	0.19	<2E-16	3	1						
			360D-main	3075.6	0	0.24	2E-09	3	1						
			540D-main	2958.2	0	0.24	0.136	3	1						
			720D-main	3000.8	0	0.19	0.0004	3	1						
		43826601	25D-main	1353	0	0.65	0.095	3	1	0.584	0.643	0.708			
			88D-main	1427.2	24.243	0.49	0.922	4	0						
	M	41119901	30D-main	2657.3	0	0.25	0.0437	3	1	0.196	0.234	0.279	0.199	0.351	0.619
			90D-main	2987.9	0	0.19	0.00026	3	1						
			180D-main	2779	0	0.15	0.619	3	1						
			360D-main	3143.6	0	0.3	1.1E-06	3	1						
			540D-main	2702.5	0	0.25	0.176	3	1						
			720D-main	2999.2	0	0.28	<2E-16	3	1						
		43826601	24D-main	1151.1	0	0.48	0.301	4	0	0.423	0.532	0.668			
			87D-main	1596.3	65.936	0.76	0.538	4	0						
Plasma	F	41119901	30D-main	1119.4	381.8	0.62	0.965	4	0	0.342	0.461	0.623	0.228	0.335	0.49
			90D-main	1962.4	484.48	0.65	0.659	4	0						
			180D-main	2150.5	90.01	0.38	0.536	4	0						
			360D-main	2351.3	500.91	0.63	0.31	4	0						
			540D-main	2276.2	0	0.41	0.0101	3	1						
			720D-main	2237.2	0	0.24	0.0168	3	1						
		43826601	25D-main	1762.1	0	0.27	0.0972	4	0	0.244	0.263	0.283			
			88D-main	2554.3	0	0.24	0.403	4	0						
	M	41119901	30D-main	409.91	0	0.05	0.00833	3	1	0.0706	0.137	0.265	0.14	0.222	0.35
			90D-main	489.36	0	0.22	4.8E-10	4	0						
			180D-main	554.06	0	0.04	0.00097	3	1						
			360D-main	726.86	0	0.07	0.0215	3	1						
			540D-main	726.86	0	0.07	0.0492	3	1						
			720D-main	911.41	0	0.33	0.0171	4	0						
		43826601	24D-main	564.39	40.154	0.22	0.325	4	0	0.196	0.285	0.415			
			87D-main	599.02	137.5	0.3	0.553	4	0						

Azinphos Methyl Figure 1. - Potency Versus Duration of Exposure Graphs

	BRAIN	RBC	PLASMA
F			
M			

Azinphos Methyl Figure 2. - Brain Female Results of Dose-Reponse Analysis: Dose-Reponse Curves for Oral Route of Exposure



Azinphos Methyl Figure 3. - Brain Male Results of Dose-Reponse Analysis: Dose-Reponse Curves for Oral Route of Exposure



Azinphos Methyl Figure 4. - Plasma Female Results of Dose-Reponse Analysis: Dose-Reponse Curves for Oral Route of Exposure



Azinphos Methyl Figure 5. - Plasma Male Results of Dose-Reponse Analysis: Dose-Reponse Curves for Oral Route of Exposure



Azinphos Methyl Figure 6. - RBC Female Results of Dose-Reponse Analysis: Dose-Reponse Curves for Oral Route of Exposure



Azinphos Methyl Figure 7. - RBC Male Results of Dose-Reponse Analysis: Dose-Reponse Curves for Oral Route of Exposure



Bensulide

Bensulide Table 1. - Toxicology Profile Table

Bensulide						
MRID #	Guideline No.	Study Type	HED Doc. No.	Dose	Guideline/ Nonguideline	Species/ Strain
43919601	82-1 (870.3100)	13-Week Subchronic Dietary Toxicity Study in Rats	12289	0/0, 5/5, 15/15, 45/46, or 100/110 mg/kg/day (females/males)	Guideline	Rats/ Sprague Dawley
44161101	83-5 (870.4300)	Combined Chronic Toxicity and Carcinogenicity Study in Rats	12289	0/0, 1/1, 15.30/15.10, 61.30/60.10 mg/kg/day (females/males)	Guideline	Rats/ Sprague Dawley
44801101 44809401	82-2 (870.3200)	Special 21-Day Dermal Toxicity in Rats	013532	0, 30, 50, 500 mgk/kg/day	Nonguideline	Rats/ CD

Bensulide Table 2. - Results of Dose-Response Analysis: Exponential Parameter Estimates for Oral Route of Exposure

Bensulide															
Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency
Brain	F	43919601	91D-whole	20.18	0	0.008	0.419	5	0	0.00653	0.00845	0.0109	0.00697	0.00798	0.00914
		44161101	175D-whole	13.5	0	0.008	0.015	4	0	0.00666	0.00781	0.00916			
			357D-whole	13.77	0	0.008	0.216	4	0						
			539D-whole	12.38	0.905	0.006	0.906	4	0						
			721D-whole	10.58	0	0.005	0.007	4	0						
	M	43919601	91D-duplicate	21.34	12.227	0.035	0.677	4	0	0.0117	0.0348	0.103	0.0117	0.0348	0.103
			91D-whole	20.73	0	0.004	0.097	5	0	0.00304	0.00428	0.00603	0.00338	0.0043	0.00546
		44161101	175D-whole	13.75	7.1969	0.01	0.805	4	0	0.00309	0.00431	0.00603			
			357D-whole	13.43	0	0.004	0.432	4	0						
			721D-whole	10.73	0	0.005	0.236	4	0						
RBC	F	43919601	91D-main	733	0	0.011	0.88	5	0	0.00944	0.011	0.0129	0.00974	0.0113	0.0132
		44161101	175D-main	1308	437.26	0.032	0.492	4	0	0.0101	0.0216	0.046			
			357D-main	1461	184.08	0.038	0.595	4	0						
			539D-main	1094	284.14	0.029	0.135	4	0						
			721D-main	1062	0	0.009	0.903	4	0						
Plasma	F	43919601	91D-main	2334	210.06	0.057	0.338	5	0	0.0496	0.0567	0.0648	0.0514	0.0721	0.101
			175D-main	2878	334.05	0.114	0.172	4	0	0.0794	0.0924	0.107			
			357D-main	2695	190.97	0.098	0.724	4	0						
			539D-main	2467	280.99	0.091	0.087	4	0						
			721D-main	2372	237.77	0.066	0.183	4	0						
	M	43919601	91D-main	518.2	188.86	0.042	0.7	5	0	0.0297	0.0421	0.0595	0.0368	0.0638	0.111
			175D-main	587.1	242.75	0.054	0.221	4	0	0.0728	0.0932	0.119			
			357D-main	831.5	281.18	0.091	0.083	4	0						
			539D-main	950.6	307.75	0.115	0.656	4	0						
			721D-main	1087	267.67	0.087	0.863	4	0						
	M	43919601	91D-main	500.3	167.03	0.026	0.138	5	0	0.0112	0.0257	0.0588	0.0151	0.0257	0.0438
		44161101	175D-main	1011	476.66	0.055	0.375	4	0	0.0129	0.0258	0.0516			
			357D-main	1446	581.85	0.033	0.083	4	0						
			539D-main	1012	405.6	0.022	0.973	4	0						
			721D-main	1133	0	0.013	0.457	4	0						

Bensulide Figure 1. - Potency Versus Duration of Exposure Graphs

	BRAIN	RBC	PLASMA
F			
M			

Bensulide Figure 2. - Brain Female Results of Dose-Reponse Analysis: Dose-Reponse Curves for Oral Route of Exposure



Bensulide Figure 3. - Brain Male Results of Dose-Reponse Analysis: Dose-Reponse Curves for Oral Route of Exposure



Bensulide Figure 4. - Plasma Female Results of Dose-Reponse Analysis: Dose-Reponse Curves for Oral Route of Exposure



Bensulide Figure 5. - Plasma Male Results of Dose-Reponse Analysis: Dose-Reponse Curves for Oral Route of Exposure



Bensulide Figure 6. - RBC Female Results of Dose-Reponse Analysis: Dose-Reponse Curves for Oral Route of Exposure



Bensulide Figure 7. - RBC Male Results of Dose-Reponse Analysis: Dose-Reponse Curves for Oral Route of Exposure



Chlorpyrifos

Chlorpyrifos Table 1. - Toxicology Profile Table

Chlorpyrifos						
MRID #	Guideline No.	Study Type	HED Doc. No.	Dose	Guideline/ Nonguideline	Species/ Strain
40436406	82-1 (870.3100)	Subchronic Feeding in Rats (90 days)	006851 007302 013240	0/0, 0.05/0.04, 1.00/0.90, 23.40/19.40 mg/kg/day (females/males)	Guideline	Rat/ Sprague Dawley
40952801	82-1 (870.3100)	Subchronic Feeding in Rats (90 days)	007102	0, 0.10, 1.00, 5.00, 15.00 mg/kg/day	Guideline	Rat/ CDF Fischer 344
42172802	83-5 (870.4300)	Chronic Feeding/Carcinogenicity Study in F344 rats (2 yrs)	009733 010605 013240	0/0, 0.01/0.01, 0.37/0.33, 7.61/6.77 mg/kg/day (females/males)	Guideline	Rat/ Fischer 344
40952802	83-5 (870.4300)	Chronic Feeding/Carcinogenicity Study in F344 rats (2 yrs)	007107 013240	0, 0.05, 0.10, 1, 10 mg/kg/day	Guideline	Rat/ Fischer 344

Chlorpyrifos Table 2. - Results of Dose-Response Analysis: Exponential Parameter Estimates for Oral Route of Exposure

Chlorpyrifos															
Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency
Brain	F	40952801	91D-whole	11.88	0	0.01	0.789	3	2	0.000339	0.00976	0.281	0.0714	0.111	0.172
		40952802	360D-whole	11.76	0	0.048	0.0814	4	1	0.0796	0.0854	0.0916			
			720D-whole	9.003	0	0.086	0.604	5	0						
		42172802	350D-whole	5.166	0	0.184	0.0493	4	0	0.132	0.161	0.198			
			728D-whole	3.706	0	0.137	0.327	4	0						
	M	40952801	90D-whole	11.33	0	0.023	0.61	3	2	0.00721	0.0227	0.0717	0.027	0.11	0.448
		40952802	360D-whole	11.12	0	0.71	0.231	3	2	0.0522	0.228	0.992			
			720D-whole	9.044	0	0.084	0.00375	5	0						
		42172802	350D-whole	6.068	2.279	1.207	0.844	4	0	0.0741	0.337	1.53			
			728D-whole	3.204	0	0.13	0.0496	4	0						
RBC	F	40952801	44D-main	1836	0	0.437	0.413	3	2	0.338	0.707	1.48	0.0153	0.0894	0.52
			91D-main	1879	902.7	1.286	0.64	5	0						
		40952802	180D-main	1748	0	0.014	0.796	5	0	0.0154	0.0504	0.165			
			360D-main	1891	0	0.049	0.22	5	0						
			540D-main	2000	0	0.306	0.339	4	1						
			720D-main	2086	0	0.019	0.133	5	0						
		42172802	350D-main	2402	2119	0.421	0.554	4	0	0.0105	0.0196	0.0365			
			546D-main	2132	0	0.014	0.0383	4	0						
			728D-main	2684	0	0.031	0.253	4	0						
	M	40952801	43D-main	2096	0	0.397	0.949	3	2	0.0972	0.223	0.512	0.0511	0.102	0.206
			90D-main	1412	0	0.119	0.288	4	1						
		40952802	180D-main	2467	0	0.281	0.207	4	1	0.0375	0.117	0.363			
			360D-main	1908	0	0.041	0.305	5	0						
			540D-main	2035	0	0.448	0.447	4	1						
			720D-main	1565	0	0.033	0.223	5	0						
		42172802	350D-main	2811	0	0.055	0.0483	4	0	0.0424	0.0589	0.0816			
			546D-main	Did not converge to exponential function											
			728D-main	2276	0	0.075	0.232	4	0						

Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency
Plasma	F	40436406	84D-main	3694	0	2.515	0.0109	3	1	2.32	2.52	2.73	1.65	1.94	2.28
		0952801	44D-main	2980	0	1.71	0.924	3	2	1.64	1.71	1.78			
			91D-main	3431	0	1.708	0.246	3	2						
		40952802	180D-main	3777	619.6	1.559	0.644	5	0	1.39	1.71	2.12			
			360D-main	4490	199.8	2.435	0.142	5	0						
			540D-main	3983	490.1	1.609	0.376	5	0						
			720D-main	2991	509.6	1.378	0.453	5	0						
		42172802	98D-main	3741	716.1	2.042	0.083	4	0	1.69	1.86	2.04			
			224D-main	3821	573.8	2.122	0.661	4	0						
			315D-main	4238	326.6	1.937	0.39	4	0						
			350D-main	4072	82.33	1.892	0.613	4	0						
			546D-main	4001	112.7	1.741	0.557	4	0						
			728D-main	3582	158.4	1.194	0.519	4	0						
	M	40436406	84D-main	592.2	0	0.401	0.0015	3	1	0.284	0.401	0.565	0.467	0.678	0.986
		40952801	43D-main	631.6	0	0.716	0.12	3	2	0.691	0.787	0.898			
			90D-main	633.3	0	0.865	0.511	3	2						
		40952802	180D-main	713.7	0	0.484	0.874	4	1	0.698	1.17	1.97			
			360D-main	943.5	119.8	1.747	0.0953	5	0						
			540D-main	1433	331.1	1.686	0.524	5	0						
			720D-main	1721	350.3	1.345	0.847	5	0						
		42172802	98D-main	811.4	328.5	0.816	0.613	4	0	0.33	0.601	1.1			
			224D-main	1014	0	0.145	0.313	4	0						
			315D-main	993.7	148.2	0.743	0.409	4	0						
			350D-main	995.1	52	0.57	0.397	4	0						
			546D-main	1404	94.17	1.082	0.541	4	0						
			728D-main	1711	87.12	1.082	0.727	4	0						

Chlorpyrifos Figure 1. - Potency Versus Duration of Exposure Graphs

	BRAIN	RBC	PLASMA
F			
M			

Chlorpyrifos Figure 2. - Brain Female Results of Dose-Reponse Analysis: Dose-Reponse Curves for Oral Route of Exposure



Chlorpyrifos Figure 3. - Brain Male Results of Dose-Reponse Analysis: Dose-Reponse Curves for Oral Route of Exposure



Chlorpyrifos Figure 4. - Plasma Female Results of Dose-Reponse Analysis: Dose-Reponse Curves for Oral Route of Exposure



Chlorpyrifos Figure 5. - Plasma Male Results of Dose-Reponse Analysis: Dose-Reponse Curves for Oral Route of Exposure



Chlorpyrifos Figure 6. - RBC Female Results of Dose-Reponse Analysis: Dose-Reponse Curves for Oral Route of Exposure



Chlorpyrifos Figure 7. - RBC Male Results of Dose-Reponse Analysis: Dose-Reponse Curves for Oral Route of Exposure



Diazinon

Diazinon Table 1. - Toxicology Profile Table

Diazinon						
MRID #	Guideline No.	Study Type	HED Doc. No.	Dose	Guideline/ Nonguideline	Species/ Strain
41886301	82-1 (870.3100)	Special Subchronic Feeding Study-- 6 weeks (1991) Supplementary	009372 012219	0/0, 0.20/0.18, 0.46/0.45, 1.98/1.85, 19.73/18.06, 97.77/90.78, 301.98/272.67 mg/kg/day (female/male)	Nonguideline	Rat/ Sprague Dawley
40815003	82-1 (870.3100)	90-Day Subchronic Feeding Study Rat Supplementary	007041 007553 012219	0/0, 0.04/0.03, 0.40/0.30, 19/15, 212/168 mg/kg/day (females/males)	Guideline	Rat/ Sprague Dawley
43543902	82-7 (870.6200)	Subchronic Neurotoxicity Rat (1994)	011873	0, 0.3, 30, 300 or 3000 ppm 0/0, 0.02/0.02, 2.00/1.78, 20/18.20, 217/187 mg/kg/day (females/males)	Guideline	Rat/ Sprague Dawley
41942002	83-1 (870.4100)	One-Year Chronic Toxicity in Rat (1991) Acceptable	010331 012219	0, 0.005/0.004, 0.07/0.06, 6/5, or 12/10 mg/kg/day (males/females)	Guideline	Rat/ Sprague Dawley
43543901	82-7 (870.6200)	Special ChE Inhibition Study–28 days Supplementary	011873	0/0, 0.02/0.02, 2.4/2.3, 23/23, and 210/213 mg/kg/day (females/males)	Nonguideline	Rat/ Sprague Dawley

Diazinon Table 2. - Results of Dose-Response Analysis: Exponential Parameter Estimates for Oral Route of Exposure

Diazinon															
Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency
Brain	F	40815003	87D-whole	3146	0	0.0281	0.155	4	1	0.0272	0.0281	0.0291	0.00542	0.0188	0.0656
		41886301	42D-whole	65.78	0	0.0042	0.046	7	0	0.0039	0.00418	0.00447			
		41942002	370D-whole	2610	0	0.0558	0.0008	4	1	0.0547	0.0568	0.0591			
			684D-whole	2872	0	0.0571	0.0126	5	0						
	M	40815003	87D-whole	3101	0	0.0043	5E-07	5	0	0.0041	0.00425	0.00438	0.000687	0.00341	0.0169
		41886301	42D-whole	65.8	0	0.0006	0.71	7	0	0.0005	0.000601	0.000794			
		41942002	370D-whole	2802	0	0.0084	0.0011	5	0	0.0059	0.0216	0.0784			
			684D-whole	2782	0	0.054	0.681	5	0						
RBC	F	40815003	87D-main	2277	0	0.4383	0.021	3	2	0.4	0.438	0.481	0.103	0.269	0.703
		41886301	28D-main	3908	0	0.0176	0.969	6	1	0.0146	0.0323	0.0715			
			42D-main	5093	537.4	0.0556	0.0764	7	0						
		41942002	88D-main	3455	0	0.6886	0.0344	3	2	0.0693	0.22	0.699			
			181D-main	3470	0	0.7208	0.656	3	2						
			356D-main	3320	0	0.0437	5E-05	4	1						
			552D-main	3435	0	0.5553	6E-05	3	2						
			684D-main	3320	0	0.0468	0.0673	4	1						
		43543901	28D-main	1386	200	0.4741	0.423	5	0	0.244	0.474	0.92			
		43543902	28D-main	1383	230	0.5694	0.589	5	0	0.532	0.74	1.03			
			56D-main	1629	241.9	0.6085	0.131	5	0						
			91D-main	1499	326	1.0358	0.456	5	0						
	M	40815003	87D-main	2125	0	0.022	0.0011	4	1	0.0206	0.022	0.0236	0.036	0.145	0.585
		41886301	28D-main	5137	0	0.0444	0.786	5	2	0.0407	0.0439	0.0473			
			42D-main	4618	0	0.0433	0.0492	5	2						
		41942002	88D-main	3016	0	0.0359	0.575	4	1	0.0257	0.0811	0.256			
			181D-main	3449	0	0.0354	0.005	4	1						
			356D-main	3125	0	0.0397	3E-08	4	1						
			552D-main	3604	0	0.0661	0.389	4	1						
			684D-main	3042	0	1.1665	0.0008	3	2						
		43543901	28D-main	1818	568	0.7973	0.187	5	0	0.435	0.797	1.46			
		43543902	28D-main	1672	514.2	0.9743	0.415	5	0	0.645	1.07	1.79			
			56D-main	1834	291.9	0.4624	0.32	5	0						
			91D-main	1428	224	1.6983	0.596	5	0						

Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency
Plasma	F	40815003	87D-main	2362	0	3.8246	0.417	3	2	3.7	3.82	3.95	0.535	1.52	4.33
		41886301	28D-main	6989	0	0.2136	0.248	4	3	0.191	0.298	0.463			
			42D-main	9808	0	0.4041	0.531	4	3						
		41942002	88D-main	2473	0	10.856	3E-05	3	2	6.99	8.64	10.7			
			181D-main	2750	0	9.7953	4E-05	3	2						
			356D-main	2509	0	9.8266	0.0003	3	2						
			552D-main	2687	0	7.7568	0.0026	3	2						
			684D-main	2318	0	4.368	0.0343	3	2						
		43543901	28D-main	1300	83.01	0.7391	0.0699	5	0	0.569	0.739	0.96			
		43543902	28D-main	1268	0	0.8195	0.207	3	2	0.839	1.07	1.36			
			56D-main	1669	0	1.0711	0.639	3	2						
			91D-main	2262	0	1.3789	0.565	3	2						
	M	40815003	87D-main	419.1	0	1.2296	9E-07	3	2	1.06	1.23	1.42	0.0944	0.312	1.03
		41886301	28D-main	2268	0	0.0309	0.844	5	2	0.0261	0.0305	0.0355			
			42D-main	2063	0	0.0301	0.748	5	2						
		41942002	88D-main	412.2	72.35	6.545	0.0543	5	0	0.169	1.11	7.3			
			181D-main	450.6	0	0.1856	0.002	4	1						
			356D-main	523	0	0.0428	6E-07	4	1						
			552D-main	854.1	0	3.6001	0.873	3	2						
			684D-main	1051	0	9.7792	3E-05	3	2						
		43543901	28D-main	333	0	0.3002	0.697	3	2	0.23	0.3	0.392			
		43543902	28D-main	333.3	0	0.2756	0.511	3	2	0.271	0.37	0.507			
			56D-main	330.3	0	0.3387	0.792	3	2						
			91D-main	354.1	0	0.5187	0.555	3	2						

Diazinon Figure 1. - Potency Versus Duration of Exposure Graphs

	BRAIN	RBC	PLASMA
F			
M			

Diazinon Figure 2. - Brain Female Results of Dose-Reponse Analysis: Dose-Reponse Curves for Oral Route of Exposure



Diazinon Figure 3. - Brain Male Results of Dose-Reponse Analysis: Dose-Reponse Curves for Oral Route of Exposure



Diazinon Figure 4. - Plasma Female Results of Dose-Reponse Analysis: Dose-Reponse Curves for Oral Route of Exposure



Diazinon Figure 5. - Plasma Male Results of Dose-Reponse Analysis: Dose-Reponse Curves for Oral Route of Exposure



Diazinon Figure 6. - RBC Female Results of Dose-Reponse Analysis: Dose-Reponse Curves for Oral Route of Exposure



Diazinon Figure 7. - RBC Male Results of Dose-Reponse Analysis: Dose-Reponse Curves for Oral Route of Exposure



Dichlorvos

Dichlorvos Table 1. - Toxicology Profile Table

Dichlorovos						
MRID #	Guideline No.	Study Type	HED Doc. No.	Dose	Guideline/ Nonguideline	Species/ Strain
41004701	82-1	90-Day Subchronic Toxicity–Rat	007448	0, 0.1, 1.5, 15 mg/kg/day	Guideline	Rat/ Crl:DC(SD)BR
42958101	82-7 (870.6200)	90-Day Neurotoxicity– Rat	011055 012494	0, 0.1, 7.5, 15 mg/kg/day	Guideline	Rat/ Sprague Dawley Crl:CDBR
40299401	83-5 (870.4300)	Chronic Toxicity/ Carcinogenicity–Rats (NTP study)	006017 012494	0, 4, 8 mg/kg/day	Guideline	Rat/ Fischer 344
00057695 00632569	83-5 (870.3320)	Chronic Inhalation Toxicity/Carcinogenicity (Rat)	001466 006860	0, 0.05, 0.5, 5 mg/m^3	Supplemental	Rat/ Carworth Farm E (CFE)

Dichlorvos Table 2. - Results of Dose-Response Analysis: Exponential Parameter Estimates for Oral Route of Exposure

Dichlorovos															
Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency
Brain	F	41004701	98D-whole	1336.42	0	0.04	0.896	4	0	0.03	0.04	0.06	0.03	0.04	0.06
	M	41004701	98D-whole	1163.59	769.20	0.19	0.570	4	0	2.24E-03	0.19	16.70	2.24E-03	0.19	16.70
RBC	F	4029940	90D-main	1790.18	0	0.10	2.20E-04	3	0	0.09	0.10	0.11	0.07	0.23	0.78
			270D-main	1688.77	0	0.09	7.66E-07	3	0						
			540D-main	1527.32	0	0.10	0.043	3	0						
		41004701	49D-main	1216.99	0	0.16	0.247	3	1	0.13	0.16	0.20			
			98D-main	1275.61	0	0.16	0.044	3	1						
		42958101	49D-main	750.00	448.84	6.76	0.818	4	0	0.42	3.85	35.30			
			91D-main	708.36	452.97	0.36	0.881	4	0						
	M	4029940	270D-main	1743.00	0	0.05	8.44E-07	3	0	0.06	0.10	0.16	0.10	0.14	0.21
			360D-main	1712.41	0	0.16	2.00E-04	3	0						
			540D-main	1639.69	0	0.09	9.82E-04	3	0						
			720D-main	1414.71	0	0.15	3.63E-04	3	0						
		41004701	49D-main	1191.51	0	0.18	0.935	3	1	0.14	0.18	0.23			
			98D-main	1315.03	0	0.17	0.100	3	1						
Plasma	F	4029940	45D-main	1684.30	0	0.23	9.64E-07	3	0	0.23	0.25	0.26	0.12	0.18	0.29
			90D-main	2016.76	0	0.23	9.83E-07	3	0						
			180D-main	2232.54	0	0.22	6.86E-07	3	0						
			270D-main	2902.67	0	0.26	2.58E-07	3	0						
			360D-main	2431.10	0	0.26	2.69E-07	3	0						
			540D-main	2050.94	0	0.29	8.74E-07	3	0						
		41004701	49D-main	881.82	328.64	0.27	0.287	4	0	0.08	0.26	0.85			
			98D-main	1124.76	439.40	0.11	0.705	4	0						
		42958101	21D-main	1502.91	0	0.10	0.030	3	1	0.10	0.12	0.15			
			49D-main	2036.90	0	0.13	0.052	3	1						
			91D-main	2460.76	837.08	0.43	0.072	4	0						
	M	4029940	45D-main	374.48	0	0.15	4.50E-05	3	0	0.10	0.12	0.15	0.10	0.12	0.14
			90D-main	391.19	0	0.09	8.26E-07	3	0						
			180D-main	447.28	0	0.09	1.64E-06	3	0						
			270D-main	683.78	0	0.12	2.90E-07	3	0						
			360D-main	640.69	0	0.15	3.12E-04	3	0						
			540D-main	655.58	0	0.14	1.18E-04	3	0						
		41004701	49D-main	305.28	111.07	0.35	0.320	4	0	0.01	0.09	0.59			
			98D-main	289.04	0	0.02	0.267	4	0						
		42958101	49D-main	390.84	0	0.04	0.185	4	0	0.02	0.08	0.27			
			91D-main	416.00	206.32	0.24	0.940	4	0						

Dichlorvos Figure 1. - Potency Versus Duration of Exposure Graphs

	BRAIN	RBC	PLASMA
F			
M			

Dichlorvos Figure 2. - Brain Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



Dichlorvos Figure 3. - Brain Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



Dichlorvos Figure 4. - Plasma Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



Dichlorvos Figure 5. - Plasma Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



Dichlorvos Figure 6. - RBC Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



Dichlorvos Figure 7. - RBC Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure













Dimethoate

Dimethoate Table 1. - Toxicology Profile Table

Dimethoate						
MRID #	Guideline No.	Study Type	HED Doc. No.	Dose	Guideline/ Nonguideline	Species/ Strain
43128201	82-7 (870.6200)	90-Day Neurotoxicity--Rat	011164	0/0, 0.08/0.06, 3.78/3.22, 9.88/8.13 mg/kg/day (females/males)	Guideline	Rat/ Sprague Dawley
164177	83-5 (870.4300)	Chronic toxicity/ Carcinogenicity–Rats	006398 008457	0/0, 0.06/0.04, 0.30/0.23, 1.48/1.16, 6.29/4.82 mg/kg/day (females/males)	Guideline	Rat/ Wistar SPF

Dimethoate Table 2. - Results of Dose-Response Analysis: Exponential Parameter Estimates for Oral Route of Exposure

Dimethoate															
Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	#Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency
Brain	F	00164177	728D-whole	0.5074	0.1858	0.69478	0.448	5	0	0.627	0.695	0.769	0.627	0.695	0.769
	M	00164177	728D-whole	0.4711	0	1.06979	0.092	3	2	0.876	1.07	1.31	0.876	1.07	1.31
RBC	F	00164177	28D-main	25.644	0	0.94054	0.462	3	2	0.296	0.656	1.45	0.203	0.392	0.757
			91D-main	27.223	0	0.91887	0.644	3	2						
			182D-main	25.333	0	0.79933	0.006	3	2						
			364D-main	29.091	12.682	3.29323	1E-03	5	0						
			546D-main	16.292	0	0.16436	0.802	5	0						
			728D-main	24.376	0	0.22263	0.229	5	0						
		43128201	21D-main	7296.9	0	0.00116	0.225	4	0	0.124	0.252	0.51			
			49D-main	2202.6	788.99	0.2394	0.314	4	0						
			91D-main	1698.9	664.37	0.32831	0.802	4	0						
	M	00164177	28D-main	23.446	3.3802	0.55675	0.002	5	0	0.301	0.492	0.803	0.278	0.431	0.666
			91D-main	23.718	0	1.10394	3E-05	3	2						
			182D-main	21.242	0	0.32867	4E-05	3	2						
			364D-main	22.004	0	0.30493	0.007	5	0						
			546D-main	15.946	0	0.2103	2E-04	4	1						
			728D-main	28.156	0	0.94336	0.002	3	2						
		43128201	21D-main	6800.6	0	0.00895	0.538	3	1	0.0983	0.258	0.675			
			49D-main	1938.9	0	0.18148	0.076	3	1						
			91D-main	1721.9	830.38	0.82958	0.671	4	0						
Plasma	F	00164177	28D-main	33.781	0	0.12353	0.009	5	0	0.0526	0.0827	0.13	0.0567	0.0759	0.102
			91D-main	46.167	0	0.12883	0.029	5	0						
			182D-main	52.584	0	0.01863	6E-04	4	1						
			364D-main	52.567	0	0.03081	0.035	4	1						
			546D-main	35.44	0	0.07457	4E-05	4	1						
			728D-main	29.124	0	0.07529	0.003	4	1						
		43128201	21D-main	2854.1	0	0.07433	0.288	4	0	0.0488	0.0714	0.104			
			49D-main	2241.1	0	0.07591	0.214	4	0						
			91D-main	2497.7	0	0.05919	0.27	4	0						
	M	00164177	28D-main	9.7775	0	0.16352	0.225	5	0	0.159	0.166	0.173	0.159	0.166	0.173
			91D-main	12.674	1.7228	0.21162	0.206	5	0						
			182D-main	13.505	0	0.06484	3E-04	4	1						
			364D-main	16.35	0	0.16065	0.382	5	0						
			546D-main	16.09	0	0.17781	7E-04	5	0						
			728D-main	16.94	0	0.16097	8E-04	5	0						
		43128201	21D-main	637.55	404.17	0.20278	0.718	4	0	0.151	0.328	0.71			
			49D-main	360.51	127.21	0.13992	0.844	4	0						
			91D-main	370.78	192.6	0.40725	0.562	4	0						

Dimethoate Figure 1. - Potency Versus Duration of Exposure Graphs

	BRAIN	RBC	PLASMA
F			
M			

Dimethoate Figure 2. - Brain Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



Dimethoate Figure 3. - Brain Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



Dimethoate Figure 4. - Plasma Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



Dimethoate Figure 5. - Plasma Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



Dimethoate Figure 6. - RBC Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



Dimethoate Figure 7. - RBC Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



Disulfoton

Disulfoton Table 1. - Toxicology Profile Table

Disulfoton						
MRID #	Guideline No.	Study Type	HED Doc. No.	Dose	Guideline/ Nonguideline	Species/ Strain
00162338	82-2 (870.3200)	21-day Dermal Toxicity–Rabbit	005556	0, 0.4, 1.6, 6.5 mg/kg/day	Guideline	Rabbit/ New Zealand
41224301	82-4 (870.3465)	Subchronic Inhalation–Rat	011242	Air and PEG-400:50% ethanol vehicle controls, 0.016/0.018, 0.16/0.16, 1.4/1.4 mg/m^3 (females/males)	Guideline	Rat/ Fischer 344
42977401	82-7 (870.6200)	Subchronic Neurotoxicity–Rat	011456	0/0, 0.07/0.06, 0.31/0.27, 1.30/1.08 mg/kg/day (females/males)	Guideline	Rat/ Fischer 344
43058401	Non-guideline study	Special 6-month Cholinesterase–Rat	011249	0/0, 0.02/0.02, 0.03/0.03, 0.07/0.06 mg/kg/day (females/males)	Nonguideline	Rat/ Fischer CDF (F-344) BR
41850002	83-5 (870.4300)	Chronic Toxicity/carcinogenicity–Rat	005029	0/0, 0.08/0.06, 0.26/0.22, 1.25/0.92 mg/kg/day (females/males)	Guideline	Rat/ Fischer 344
45239601	82-2 (870.3200)	21-day Dermal Toxicity–Rabbit	014448	0, 0.8, 1, 3 mg/kg/day	Guideline	Rabbit/ New Zealand White (HC:NZW)

Disulfoton Table 2. - Results of Dose-Response Analysis: Exponential Parameter Estimates for Oral Route of Exposure

Disulfoton															
Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency
Brain	F	41850002	735D-whole	14.4202	2.49333	3.932	0.948	4	0	3.05	3.93	5.07	1.99	2.91	4.24
		42977401	91D-whole	15.2965	0	3.378	0.00283	3	1	3.19	3.38	3.58			
		43058401	60D-whole	16.4585	0	1.058	0.00374	4	0	1.22	1.71	2.4			
			116D-whole	15.7483	0	2.059	0.888	4	0						
			179D-whole	15.6931	0	2.114	0.084	4	0						
	M	41850002	735D-whole	14.636	2.9005	5.034	0.135	4	0	4.39	5.03	5.77	0.654	1.82	5.06
		42977401	91D-whole	14.5192	0	1.7	0.0221	3	1	1.51	1.7	1.92			
		43058401	59D-whole	15.7717	0	0.05	0.191	4	0	0.133	0.438	1.44			
			115D-whole	15.5271	0	0.478	0.00437	4	0						
			178D-whole	15.6547	0	0.303	0.0664	4	0						
RBC	F	41850002	98D-main	1717.67	0	4.548	0.000242	3	1	4.04	4.64	5.32	4.43	4.87	5.36
			189D-main	1728.19	0	4.656	0.000559	3	1						
			371D-main	1615.13	0	4.962	0.00264	3	1						
			553D-main	1640.13	0	5.769	0.00121	3	1						
			735D-main	1566.59	0	3.428	0.0262	3	1						
		42977401	24D-main	1711.86	17.8716	5.138	0.963	4	0	4.87	5.35	5.87			
			87D-main	1534.9	0	5.348	0.00199	3	0						
		43058401	57D-main	1571.12	0	4.548	0.363	4	0	3.9	4.47	5.12			
			113D-main	1525.42	0	4.953	0.666	4	0						
			176D-main	1509.95	0	3.827	0.0951	4	0						
	M	41850002	98D-main	1786.69	500.183	5.428	0.195	4	0	3.34	4.34	5.64	2.94	3.55	4.28
			189D-main	1910.03	0	2.899	0.00129	3	1						
			371D-main	1900.5	0	3.216	0.129	3	1						
			553D-main	1843.76	0	5.164	0.0188	3	1						
			735D-main	1559.25	304.353	6.02	0.142	4	0						
		42977401	24D-main	1774.01	0	3.597	0.0567	3	0	3.25	3.69	4.18			
			87D-main	1728.58	79.0147	4.645	0.602	4	0						
		43058401	56D-main	1490.14	0	2.724	0.441	4	0	1.96	2.62	3.5			
			112D-main	1437.44	0	1.98	0.14	4	0						
			175D-main	1642.76	0	3.082	3.86E-05	4	0						
Plasma	F	41850002	98D-main	2434.4	118.345	5.833	0.37	4	0	4.9	5.22	5.55	2.71	3.74	5.16
			189D-main	3304.57	167.352	5.717	0.0743	4	0						
			371D-main	3224.44	0	5.048	0.0479	3	1						
			553D-main	3310.46	0	4.94	0.0143	3	1						
			735D-main	2894.5	124.514	4.976	0.441	4	0						
		42977401	24D-main	1606.95	130.606	3.335	0.402	4	0	3.14	3.54	3.98			
			87D-main	2673.95	70.9379	3.783	0.183	4	0						
		43058401	57D-main	1706.71	1519.16	19.9	0.506	4	0	1.76	2.51	3.57			
			113D-main	2190.91	0	1.891	0.301	4	0						
			176D-main	2683.67	0	2.71	0.752	4	0						

Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency
Plasma (con't)	M	41850002	98D-main	562.713	0	1.121	0.796	4	0	1.08	1.89	3.31	0.997	1.41	2.01
			189D-main	899.626	130.842	1.94	0.176	4	0						
			371D-main	793.35	0	0.78	0.0485	3	1						
			553D-main	1120.82	128.066	2.715	0.585	4	0						
			735D-main	1676.49	70.7145	4.815	0.207	4	0						
		42977401	24D-main	644.876	0	1.084	0.000268	4	0	1.02	1.1	1.18			
			87D-main	670.794	66.6236	1.635	0.129	4	0						
		43058401	56D-main	584.792	0	2.633	0.152	3	1	1.1	2.11	4.06			
			112D-main	629.363	0	0.108	0.137	4	0						
			175D-main	687.771	0	1.378	0.000942	4	0						

Disulfoton Figure 1. - Potency Versus Duration of Exposure Graphs

	BRAIN	RBC	PLASMA
F			
M			

Disulfoton Figure 2. - Brain Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



Disulfoton Figure 3. - Brain Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



Disulfoton Figure 4. - Plasma Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



Disulfoton Figure 5. - Plasma Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



Disulfoton Figure 6. - RBC Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



Disulfoton Figure 7. - RBC Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



Fenamiphos

Fenamiphos Table 1. - Toxicology Profile Table

Fenamiphos						
MRID #	Guideline No.	Study Type	HED Doc. No.	Dose	Guideline/ Nonguideline	Species/ Strain
00154497	82-2 (870.3200)	21-Day Dermal Toxicity–Rabbit	004531 005722	0, 0.5, 2.5, 10 mg/kg/day	Guideline	Rabbit/ New Zealand White
40774809	82-4 (870.3465)	21-Day Inhalation Toxicity–Rat (nose only)	004531 010301 011035	0, 0.03, 0.25, 3.5 Fg/L	Guideline	Rat/ Wistar Albino
00161361	83-5 (870.4300)	Chronic toxicity/Carcinogenicity– Rat	003331 003606 005722	0/0, 0.12/0.10, 0.60/0.46, 3.36/2.45 mg/kg/day (females/males)	Guideline	Rat/ Fischer
44051401	82-7 (870.6200)	Subchronic Neurotoxicity–Rat	012019	0/0, 0.08/0.06, 0.80/0.61, 3.98/3.13 mg/kg/day (females/males)	Guideline	Rat/ Wistar

Fenamiphos Table 2. - Results of Dose-Response Analysis: Exponential Parameter Estimates for Oral Route of Exposure

Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency
Brain	F	00161361	763D-whole	12.28	0	0.03	0.893	4	0	0.01	0.03	0.08	0.03	0.0387 (brain-female)	0.05
		44051401	105D-whole	12.23	0	0.04	0.048	4	0	0.03	0.04	0.05			
	M	00161361	763D-whole	12.95	0	0.05	0.322	4	0	0.03	0.05	0.08	0.03	0.049 (brain-male)	0.08
		44051401	105D-whole	11.98	0	0.02	0.328	4	0	3.13E-03	0.02	0.14			
RBC	F	00161361	42D-main	1797.64	325.92	1.23	0.084	4	0	0.69	0.88	1.11	0.60	0.753 (RBC-female)	0.95
			70D-main	1878.24	271.05	0.77	2.21E-04	4	0						
			105D-main	1791.57	0	0.73	2.69E-03	3	1						
			189D-main	1700.35	269.68	1.06	6.70E-03	4	0						
			371D-main	1787.61	0	0.57	0.089	3	1						
			546D-main	1920.13	421.92	1.31	0.997	4	0						
			742D-main	1676.75	412.56	0.51	0.385	4	0						
		44051401	28D-main	867.26	0	0.51	0.809	4	0	0.48	0.63	0.83			
			105D-main	814.11	0	0.77	0.055	4	0						
	M	00161361	42D-main	1938.57	0	0.68	0.346	4	0	0.35	0.46	0.59	0.44	0.56 (RBC-male)	0.72
			70D-main	1860.06	0	0.30	0.197	3	1						
			105D-main	1879.95	0	0.63	0.911	4	0						
			189D-main	1866.37	0	0.55	0.059	3	1						
			371D-main	1904.47	0	0.32	5.03E-03	3	1						
			742D-main	1673.77	0	0.34	0.685	4	0						
		44051401	28D-main	867.28	0	0.69	0.094	4	0	0.54	0.66	0.79			
			105D-main	699.89	0	0.46	0.719	3	1						

Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency
Plasma	F	00161361	42D-main	1911.29	213.16	3.66	4.05E-03	4	0	2.85	3.21	3.62	1.91	2.6 (plasma-female)	3.54
			70D-main	2148.30	0	2.34	5.09E-04	3	1						
			105D-main	2423.51	291.67	3.25	8.87E-03	4	0						
			189D-main	2582.73	221.92	3.66	0.078	4	0						
			371D-main	3180.00	179.98	3.60	Insufficient degrees of freedom to compute a GOF	3	0						
			546D-main	2597.80	151.12	3.42	0.107	4	0						
			742D-main	2097.87	219.51	2.90	0.535	4	0						
		44051401	28D-main	1170.79	150.06	1.88	0.241	4	0	1.71	2.06	2.48			
			105D-main	1634.20	171.40	2.18	0.181	4	0						
	M	00161361	42D-main	759.56	226.51	2.02	0.129	4	0	0.83	1.42	2.44	0.82	1.22 (plasma-male)	1.83
			70D-main	614.37	145.55	0.61	0.817	4	0						
			105D-main	630.87	262.07	1.23	0.924	4	0						
			371D-main	783.76	157.95	0.88	0.069	4	0						
			546D-main	1042.33	0	0.80	8.38E-04	3	0						
			742D-main	1317.49	320.25	4.98	0.973	4	0						
		44051401	28D-main	422.65	109.71	0.75	0.471	4	0	0.55	1.01	1.85			
			105D-main	492.78	151.79	1.18	0.420	4	0						

Fenamiphos Figure 1. - Potency Versus Duration of Exposure Graphs

	BRAIN	RBC	PLASMA
F			
M			

Fenamiphos Figure 2. - Brain Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



Fenamiphos Figure 3. - Brain Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



Fenamiphos Figure 4. - Plasma Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



Fenamiphos Figure 5. - Plasma Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



Fenamiphos Figure 6. - RBC Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



Fenamiphos Figure 7. - RBC Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



Fosthiazate

Fosthiazate Table 1. - Toxicology Profile Table

Fosthiazate*						
MRID #	Guideline No.	Study Type	HED Doc. No.	Dose	Guideline/ Nonguideline	Species/ Strain
44269908	82-7 (870.6200)	90-Day Neurotoxicity Study–Rat	In review	0/0, 0.08/0.07, 0.57/0.56, 2.5/2.4 mg/kg/day (females/males)	In review	Rat/ Charles River CD (SD)
44269905	82-1 (870.3100)	4-Week Preliminary Dietary Toxicity–Rat	In review	0, 0.03, 0.05, 0.25, 0.50, 5, 20 mg/kg/day	In review	Rat/ Charles River CD (remote SD origin)
41347632	82-1 (870.3100)	13-Week Dietary Toxicity	008039	0, 1.07, 10.7, 53.6, 429 ppm 0/0, 0.09/0.08, 0.89/0.77, 4.74/4.12, 41.03/36.37 mg/kg/day females/males	Guideline	Rat/ CD
43559703	83-5 (870.4300)	Combined Chronic Toxicity/Carcinogenicity Study–Rats Acceptable/Guideline	008039	0/0, 0.05/0.04, 0.50/0.38, 2.45/1.94, 11.69/8.34 mg/kg/day (females/males)	Guideline	Rat/ Charles River CD

*Not yet registered

Fosthiazate Table 2. - Results of Dose-Response Analysis: Exponential Parameter Estimates for Oral Route of Exposure

Fosthiazate															
Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CLfor MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency
Brain	F	41347632	91D-whole	9.8221	0	0.028	0.634	3	2	8.7E-05	0.028	8.97	0.172	0.276	0.441
		43559703	371D-whole	10.916	0	0.042	0.543	3	2	0.191	0.199	0.208			
			728D-whole	10.238	0	0.199	9E-09	5	0						
		44269905	28D-whole	10.909	1.495	0.394	0.0875	7	0	0.362	0.394	0.43			
	M	41347632	91D-whole	10.259	1.393	0.079	0.0726	5	0	0.0534	0.0787	0.116	0.0817	0.115	0.163
		43559703	371D-whole	9.024	1.596	0.516	0.0723	5	0	0.0629	0.255	1.04			
			728D-whole	9.6609	0	0.043	0.527	3	2						
		44269905	28D-whole	12.116	1.182	0.136	0.278	7	0	0.114	0.136	0.163			
RBC	F	41347632	84D-main	2076.5	143.9	0.317	0.109	5	0	0.291	0.317	0.344	0.311	0.432	0.6
		43559703	84D-main	1860.7	0	0.775	0.437	3	2	0.584	0.673	0.775			
			168D-main	2093.9	140.1	0.668	0.0036	5	0						
			196D-main	2405.8	0	0.587	4E-11	4	1						
			357D-main	1885.1	0	0.912	0.645	3	2						
			364D-main	1882.1	184.7	0.731	0.485	5	0						
			532D-main	2508.1	195.8	0.481	0.34	5	0						
			714D-main	2242.1	313.6	0.642	0.0683	5	0						
		44269905	26D-main	2064.3	204.2	0.412	0.0049	7	0	0.377	0.412	0.45			
		44269908	35D-main	133.08	77.85	0.36	0.504	4	0	0.11	0.32	0.93			
			63D-main	146.19	94.02	0.802	0.128	4	0						
			98D-main	137.48	0	0.142	0.151	4	0						
	M	41347632	84D-main	1941.7	0	0.059	0.0451	3	2	0.00571	0.0595	0.62	0.122	0.265	0.579
		43559703	84D-main	1995.3	339.5	0.796	0.501	5	0	0.531	0.618	0.718			
			168D-main	2569.8	0	0.564	6E-05	4	1						
			357D-main	2939	0	0.592	0.125	4	1						
			532D-main	3006.9	352.3	0.686	0.473	5	0						
			714D-main	2466.4	288.2	0.463	0.788	5	0						
		44269905	25D-main	2339	213.8	0.377	0.847	7	0	0.353	0.377	0.402			
		44269908	35D-main	133.22	0	0.077	0.0143	4	0	0.0793	0.114	0.162			
			63D-main	139.78	0	0.099	0.224	4	0						
			98D-main	136.53	0	0.165	0.0353	4	0						

Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CLfor MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency
Plasma	F	41347632	84D-main	4111.8	0	0.852	0.0997	3	2	0.671	0.852	1.08	1.03	1.31	1.66
		43559703	84D-main	3759.1	0	1.846	4E-06	3	2	1.48	1.67	1.89			
			168D-main	5015.9	0	2.104	0.0002	3	2						
			196D-main	4294.9	0	1.482	0.0002	3	2						
			357D-main	4214.7	0	1.974	0.0017	3	2						
			364D-main	4059.4	0	1.577	0.0002	3	2						
			532D-main	4025.1	0	1.265	0.0008	3	2						
			714D-main	3779.9	0	1.521	0.67	3	2						
		44269905	26D-main	2541.4	0	1.334	0.491	5	2	1.07	1.33	1.67			
		44269908	35D-main	1478	205.3	1.25	0.254	4	0	1.21	1.44	1.71			
			63D-main	2041.2	224.5	1.615	0.91	4	0						
			98D-main	2102.7	142	1.351	0.24	4	0						
	M	41347632	84D-main	840.51	324.4	0.343	0.113	5	0	0.252	0.343	0.469	0.161	0.318	0.629
		43559703	84D-main	666.05	301.3	0.674	0.747	5	0	0.705	0.847	1.02			
			168D-main	851.04	370.7	0.827	0.238	5	0						
			357D-main	978.89	313.1	0.994	0.388	5	0						
			532D-main	1332.1	0	0.437	0.0004	3	2						
			714D-main	2084.4	470.4	1.117	0.174	5	0						
		44269905	25D-main	695.51	0	0.121	0.15	6	1	0.102	0.121	0.144			
		44269908	35D-main	519.22	0	0.221	0.533	4	0	0.243	0.292	0.351			
			63D-main	501.87	0	0.31	0.0977	4	0						
			98D-main	471.95	197.1	0.725	0.94	4	0						

Fosthiazate Figure 1. - Potency Versus Duration of Exposure Graphs

	BRAIN	RBC	PLASMA
F			
M			

Fosthiazate Figure 2. - Brain Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



Fosthiazate Figure 3. - Brain Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



Fosthiazate Figure 4. - Plasma Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



Fosthiazate Figure 5. - Plasma Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



Fosthiazate Figure 6. - RBC Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



Fosthiazate Figure 7. - RBC Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



Malathion

Malathion Table 1. - Toxicology Profile Table

Malathion						
MRID #	Guideline No.	Study Type	HED Doc. No.	Dose	Guideline/ Nonguideline	Species/ Strain
41054201	82-2 (870.3200)	21-Day Dermal–Rabbit (1988) (Malathion Technical 94% a.i.)	008714 009385 012433	0, 50, 300, 1000 mg/kg/day	Guideline	Rabbit/ New Zealand Albino
43266601	82-4 (870.3465)	13-Week Inhalation– Rat (1994) (Malathion Technical 96.4% a.i.)	012433 011516	0 (air), 0.1, 0.45, 2.01 mg/L	Nonguideline	Rat/ Sprague Dawley
43942901	83-5 (870.4300)	Combined Chronic Toxicity/Carcinogenicity–F344 Rats (1996) (Malathion Technical 97.1% a.i.)	013822 014120 014121	0/0, 5/4 , 35/29, 415/359, 868/739 mg/kg/day (females/males)	Guideline	Rat/ CDF(F-344)CrlBR
43269501	82-7 (870.6200)	Subchronic Neurotoxicity–Rat (Malathion Technical 96.4%)	14120	0/0, 4/4, 395/352, 1575/1486 mg/kg/day (females/males)	Guideline	Rat/ Sprague Dawley

Malathion Table 2. - Results of Dose-Response Analysis: Exponential Parameter Estimates for Oral Route of Exposure

Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency
Brain	F	43942901	91D-whole	10.71	0	3.89E-04	0.506	4	1	3.70E-04	4.06E-04	4.45E-04	3.70E-04	4.06E-04	4.45E-04
			182D-whole	9.82	0	4.15E-04	0.272	4	1						
			364D-whole	9.99	0	3.73E-04	0.685	5	0						
			728D-whole	10.73	0	4.84E-04	0.986	4	1						
	M	43942901	91D-whole	10.81	0	3.80E-04	0.943	4	1	2.17E-04	3.85E-04	6.81E-04	2.17E-04	3.85E-04	6.81E-04
			182D-whole	9.90	0	2.70E-04	0.491	5	0						
			364D-whole	9.80	0	2.18E-04	0.175	5	0						
			728D-whole	10.72	0	1.03E-03	0.982	4	0						
RBC	F	43269501	21D-main	1020.28	358.85	4.09E-03	0.657	4	0	2.75E-03	3.69E-03	4.94E-03	3.12E-03	4.10E-03	5.39E-03
			49D-main	889.73	298.97	4.02E-03	0.877	4	0						
			91D-main	1230.41	384.84	3.24E-03	0.893	4	0						
		43942901	91D-main	1304.80	0	7.64E-03	0.033	3	2	3.82E-03	7.88E-03	1.62E-02			
			182D-main	1407.39	572.56	3.37E-03	0.716	5	0						
			364D-main	1490.62	747.39	5.87E-03	0.304	5	0						
			728D-main	1380.46	704.68	0.02	0.172	5	0						
	M	43269501	21D-main	898.38	409.21	8.83E-03	0.612	4	0	3.49E-03	5.28E-03	8.00E-03	2.93E-03	4.24E-03	6.13E-03
			49D-main	802.24	259.96	6.77E-03	0.978	4	0						
			91D-main	1055.59	388.75	4.22E-03	0.948	4	0						
		43942901	91D-main	1068.75	452.95	7.62E-03	0.062	5	0	1.77E-03	3.03E-03	5.19E-03			
			182D-main	1082.77	388.20	3.49E-03	0.244	5	0						
			364D-main	1430.41	542.19	3.69E-03	0.958	5	0						
			728D-main	1094.70	0	1.43E-03	0.463	4	0						
Plasma	F	43269501	21D-main	1084.21	0	5.89E-04	0.285	4	0	5.78E-04	7.18E-04	8.94E-04	6.04E-04	1.14E-03	2.13E-03
			49D-main	1599.36	0	8.19E-04	0.190	4	0						
			91D-main	1889.16	90.17	1.02E-03	0.163	4	0						
		43942901	91D-main	2955.19	0	1.87E-03	0.258	5	0	1.46E-03	1.79E-03	2.18E-03			
			182D-main	3386.66	0	1.55E-03	0.584	4	1						
			364D-main	3554.45	0	1.43E-03	0.707	5	0						
			728D-main	3444.33	0	2.45E-03	0.563	5	0						
	M	43269501	21D-main	340.64	0	4.66E-04	0.437	4	0	3.90E-04	4.62E-04	5.46E-04	4.00E-04	4.72E-04	5.58E-04
			49D-main	309.40	81.27	8.91E-04	0.983	4	0						
			91D-main	296.10	0	4.49E-04	0.537	4	0						
		43942901	91D-main	631.67	0	1.02E-03	0.342	5	0	4.67E-04	1.68E-03	6.01E-03			
			182D-main	620.25	0	7.14E-04	0.509	4	1						
			364D-main	740.34	0	7.28E-04	0.256	5	0						
			728D-main	1787.82	674.11	0.02	0.463	4	0						

Malathion Figure 1. - Potency Versus Duration of Exposure Graphs

	BRAIN	RBC	PLASMA
F			
M			

Malathion Figure 2. - Brain Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure

















Malathion Figure 3. - Brain Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure

















Malathion Figure 4. - Plasma Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



Malathion Figure 5. - Plasma Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



Malathion Figure 6. - RBC Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



Malathion Figure 7. - RBC Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



Methamidophos

Methamidophos Table 1. - Toxicology Profile Table

Methamidophos						
MRID #	Guideline No.	Study Type	HED Doc. No.	Dose	Guideline/ Nonguideline	Species/ Strain
44525301	82-2 (870.3200)	21-Day Dermal–Rat	13394	0, 0.75, 11.2, 36.5 mg/kg/day	Guideline	Rat/ Sprague Dawley
00147935	82-2 (870.3200)	21-Day Dermal–Rabbit	11779	0, 0.5, 5 mg/kg/day	Nonguideline	Rabbit/ NZW
41402401	82-3 (870.3465)	90-Day Subchronic Inhalation–Rat	011550 012826	Air and vehicle [PEG E400:ethanol] controls, 0.0011, 0.0054, 0.0231 mg/L	Guideline	Rat/ Wistar
41867201	82-1 Special ChE study	Subchronic Oral–Rat	008846 012826	0/0, 0.06/0.03, 0.06/0.07, 0.17/0.13, 0.28/0.24 mg/kg/day (females/males)	Guideline	Rat/ Fischer 344
43197901	82-7 (870-6200)	Subchronic Neurotoxicity Screening Study in Rats	011530 012826	0/0, 0.07/0.07, 0.90/0.79, 4.94/4.26 mg/kg/day (females/males)	Guideline	Rat/ Fischer 344
00148452	83-5 (870.4300)	Combined Chronic/Carcinogenicity–Rat	005313 007124 012514	0, 0.20, 0.60, 1.80, 5.40 mg/kg/day	Guideline	Rat/ Fischer 344

Methamidophos Table 2. - Results of Dose-Response Analysis: Exponential Parameter Estimates for Oral Route of Exposure

Methamidophos															
Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency
Brain	F	00148452	360D-whole	13.64	0	0.96	0.005	3	2	0.88	0.97	1.06	0.90	1.09	1.33
			720D-whole	12.32	2.84	1.00	0.439	5	0						
		41867201	35D-whole	14.94	0	1.02	0.013	4	1	0.84	0.97	1.11			
			56D-whole	14.20	0	0.85	0.322	4	1						
		43197901	87D-whole	16.64	2.38	1.38	0.431	4	0	1.27	1.38	1.50			
	M	148452	360D-whole	13.89	0	0.88	0.004	3	2	0.82	0.91	1.02	0.95	1.19	1.50
			720D-whole	11.97	2.46	0.95	0.335	5	0						
		41867201	35D-whole	15.15	0	1.22	0.051	5	0	1.16	1.23	1.31			
			56D-whole	14.48	0	1.24	0.455	5	0						
		43197901	86D-whole	15.79	2.38	1.50	0.351	4	0	1.41	1.50	1.59			
RBC	F	148452	180D-main	1500.85	0	0.95	0.069	3	2	0.94	1.09	1.26	0.70	1.00	1.44
			360D-main	1524.37	435.25	1.42	0.107	5	0						
			450D-main	1667.25	349.54	1.22	0.769	5	0						
			540D-main	1631.12	0	0.93	0.021	3	2						
			720D-main	1522.76	293.93	0.99	0.646	5	0						
		41867201	28D-main	2676.93	0	0.70	0.842	4	1	0.58	0.68	0.80			
			42D-main	2619.03	0	0.75	0.564	4	1						
			51D-main	2605.15	0	0.56	0.223	4	1						
		43197901	24D-main	1333.30	29.84	1.83	0.820	4	0	1.04	1.52	2.21			
			86D-main	1345.20	58.98	1.44	0.976	4	0						
	M	148452	180D-main	1634.60	0	0.74	0.011	4	1	0.83	0.96	1.11	0.82	1.23	1.83
			360D-main	1771.17	0	0.90	0.933	3	2						
			450D-main	1866.57	326.79	1.13	0.774	5	0						
			540D-main	1797.88	347.75	1.07	0.109	5	0						
			720D-main	1540.50	363.16	1.04	0.694	5	0						
		41867201	28D-main	2820.64	0	1.20	0.051	5	0	0.77	0.97	1.24			
			42D-main	2720.02	0	1.02	0.809	5	0						
			51D-main	2645.74	0	0.76	0.421	5	0						
		43197901	24D-main	1560.27	308.19	2.78	0.619	4	0	1.55	2.10	2.85			
			86D-main	1538.34	49.68	1.99	0.837	4	0						

Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency
Plasma	F	148452	180D-main	2273.62	179.51	0.85	0.150	5	0	0.74	0.94	1.20	0.94	1.24	1.64
			360D-main	2722.67	497.02	1.62	0.494	5	0						
			450D-main	2541.99	231.18	0.88	0.041	5	0						
			540D-main	2933.55	92.88	0.76	0.117	5	0						
			720D-main	2531.66	179.15	0.81	0.372	5	0						
		41867201	28D-main	2416.01	1331.31	5.45	0.888	5	0	1.43	3.18	7.06			
			42D-main	2080.84	0	1.40	0.011	5	0						
			51D-main	2150.00	0	5.62	4.25E-08	3	2						
		43197901	24D-main	1622.97	157.87	1.32	0.172	4	0	1.16	1.27	1.39			
			86D-main	2368.00	245.38	1.24	0.773	4	0						
	M	148452	180D-main	560.75	99.11	0.70	0.055	5	0	0.65	0.72	0.79	0.69	0.87	1.10
			360D-main	729.17	0	0.78	0.321	3	2						
			450D-main	745.82	78.80	0.51	0.075	5	0						
			540D-main	1167.20	127.25	0.70	0.143	5	0						
			720D-main	1354.04	119.47	0.74	0.077	5	0						
		41867201	28D-main	607.42	457.98	6.23	0.842	5	0	0.48	1.09	2.48			
			42D-main	531.94	0	0.66	0.001	4	1						
			51D-main	529.58	0	0.76	0.060	5	0						
		43197901	24D-main	564.70	113.51	1.00	0.722	4	0	0.92	1.03	1.15			
			86D-main	589.72	144.73	1.04	0.327	4	0						

Methamidophos Table 3. - Benchmark Dose Calculations for RBC Cholinesterase Measurements Used to Calculate the Oral POD

MRID no.	Duration of Exposure (# of days)	BMD_{10}[a]	BMDL[b]
Oral (mg/kg/day)			
148452	180	0.14	0.14
	360	0.12	0.11
	450	0.11	0.11
	540	0.12	0.12
	720	0.13	0.11
41867201	28	0.088	0.079
	42	0.10	0.082
	51	0.14	0.12
43197901	24	0.048	0.029
	86	0.055	0.043
Oral POD		0.09 mg/kg/day	0.07 mg/kg/day
Dermal (mg/kg/day)			
44525301	22	1.21	0.91
Dermal POD		1.21	0.91
Inhalation (mg/L)			
41402401	28	0.0043	0.0032
	56	0.0058	0.0030
	77	0.0024	0.0019
	91	0.017	0.010
Inhalation POD		0.0046	0.0031

[a] Benchmark dose resulting in 10% reduction in background cholinesterase activity

[b] Lower 95% confidence limit on the BMD_{10}

Methamidophos Figure 1. - Potency Versus Duration of Exposure Graphs

	BRAIN	PLASMA	RBC
F			
M			

Methamidophos Figure 2. - Brain Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



Methamidophos Figure 3. - Brain Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



Methamidophos Figure 4. - Plasma Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



Methamidophos Figure 5. - Plasma Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



Methamidophos Figure 6. - RBC Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



Methamidophos Figure 7. - RBC Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



Methamidophos Figure 8. - Results of Dose-Response Analysis: Dose-Response Curves for Dermal Route of Exposure



Methamidophos Figure 9. - Results of Dose-Response Analysis: Dose-Response Curves for Inhalation Route of Exposure



Methidathion

Methidathion Table 1. - Toxicology Profile Table

Methidathion						
MRID #	Guideline No.	Study Type	HED Doc. No.	Dose	Guideline/ Nonguideline	Species/ Strain
43582501	82-7 (870.6200)	90-Day Neurotoxicity–Rat	011659	0/0, 0.20/0.18, 0.66/0.61, 2.01/1.86, 7.19/6.36 mg/kg/day (females/males)	Guideline	Rat/ Sprague Dawley
00160260	83-5 (870.4300)	Chronic Toxicity/Carcinogenicity–Rat	005743 006587	0/0, 0.20/0.26, 2.14/2.68, 5.88/7.92 mg/kg/day (females/males)	Guideline	Rat/ Sprague Dawley

Methidathion Table 2. - Results of Dose-Response Analysis: Exponential Parameter Estimates for Oral Route of Exposure

Methidathion															
Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency
Brain	F	00160260	728D-duplicatewhole	2797.81	815.83	0.60	0.109	4	0	0.51	0.60	0.71	0.51	0.60	0.71
			364D-whole	3479.81	1054.15	1.45	0.526	4	0	0.48	0.80	1.33	0.48	0.80	1.33
			651D-whole	3019.25	1133.35	0.63	0.863	4	0						
			728D-whole	2764.94	628.17	0.54	0.678	4	0						
	M	00160260	728D-duplicate whole	2699.89	800.20	0.52	0.890	4	0	0.39	0.52	0.68	0.39	0.52	0.68
			364D-whole	3322.65	0	0.23	0.019	3	1	0.19	0.29	0.44	0.19	0.29	0.44
			651D-whole	2749.35	0	0.22	0.752	3	1						
			728D-whole	2604.31	858.28	0.53	0.946	4	0						
RBC	F	00160260	728D-duplicate	2103.87	0	0.11	0.136	3	1	0.04	0.08	0.17	0.05	0.29	1.63
			182D-main	1819.36	0	0.24	0.342	3	1						
			364D-main	2405.59	0	0.01	0.367	3	1						
			546D-main	2393.04	0	0.10	0.052	3	1						
			728D-main	1841.40	0	0.04	0.241	4	0						
		43582501	28D-main	1330.66	108.58	0.84	0.766	5	0	0.72	0.97	1.29			
			56D-main	1850.27	228.78	1.33	0.169	5	0						
			91D-main	1578.32	131.05	0.80	0.485	5	0						
	M	00160260	728D-duplicate	2103.33	1571.38	0.43	0.789	4	0	0.02	0.07	0.23	0.05	0.25	1.14
			364D-main	2409.94	0	0.03	0.053	4	0						
			546D-main	2120.06	909.32	0.06	0.190	4	0						
			728D-main	1882.83	0	0.03	0.076	4	0						
		43582501	28D-main	1214.78	89.27	0.57	0.827	5	0	0.54	0.65	0.77			
			56D-main	1836.51	295.64	0.72	0.570	5	0						
			91D-main	1677.13	150.03	0.55	0.672	5	0						
Plasma	F	00160260	728D-duplicate	1662.78	772.90	0.21	0.188	4	0	0.17	0.35	0.75	0.28	0.48	0.83
			182D-main	2464.84	1051.10	0.27	0.195	4	0						
			364D-main	2578.28	1485.38	0.42	0.154	4	0						
			546D-main	2211.93	1150.07	0.38	0.462	4	0						
			728D-main	1925.26	779.14	0.26	0.909	4	0						
		43582501	28D-main	1446.63	666.21	0.67	0.820	5	0	0.31	0.67	1.46			
	M	00160260	728D-duplicate	986.74	400.17	0.29	0.168	4	0	0.08	0.30	1.13	0.08	0.30	1.13
			182D-main	544.00	351.65	4.13	0.388	4	0						
			364D-main	801.66	543.26	0.75	0.311	4	0						
			546D-main	913.76	0	0.10	0.955	4	0						
			651D-main	992.83	340.39	0.29	0.575	4	0						
			728D-main	848.00	0	0.03	0.790	4	0						

Methidathion Figure 1. - Potency Versus Duration of Exposure Graphs

	BRAIN	PLASMA	RBC
F			
M			

Methidathion Figure 2. - Brain Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



METHIDATHION









Methidathion Figure 3. - Brain Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure











Methidathion Figure 4. - Plasma Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



Methidathion Figure 5. - Plasma Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure













Methidathion Figure 6. - RBC Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



Methidathion Figure 7. - RBC Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



Methyl Parathion

Methyl Parathion Table 1. - Toxicology Profile Table

Methyl Parathion						
MRID #	Guideline No.	Study Type	HED Doc. No.	Dose	Guideline/ Nonguideline	Species/ Strain
00074299	82-1 (870.3199)	Subchronic Feeding–Rat	001882	0, 2.5, 25, 75 ppm 0/0, 0.20/0.16, 2.10/1.64, 6.90/5.90 mg/kg/day (females/males)	Guideline	Rats/ Sprague Dawley
43490501	82-7 (870.6200)	Subchronic Neurotoxicity–Rat	012073	0, 0.5, 5, or 50 ppm 0, 0.03, 0.25, 2.5 mg/kg/day	Guideline	Rats/ Sprague Dawley
41853801	83-1 (870.4100)	Chronic Toxicity with Special Focus on Sciatic Nerve Effects	010333	0, 0.5, 2.5, 12.5, 50 ppm 0, 0.03/0.02, 0.14/0.11, 0.70/0.53, 3.09/2.21 mg/kg/day (females/males)	Nonguideline	Rats/ Sprague Dawley

Methyl Parathion Table 2. - Results of Dose-Response Analysis: Exponential Parameter Estimates for Oral Route of Exposure

Methyl Parathion															
Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency
Brain	F	41853801	360D-whole	8.630649	0	0.3947	0.0216	4	1	0.311	0.395	0.5	0.31	0.393	0.497
		00074299	90D-whole	13.76302	2.678872	0.2329	0.874	4	0	0.0221	0.233	2.45			
	M	41853801	360D-whole	7.981011	0	0.0237	0.23	4	1	0.000417	0.0237	1.35	0.0197	0.0553	0.155
		00074299	90D-whole	12.72864	0	0.0586	0.0693	3	1	0.0202	0.0586	0.17			
RBC	F	41853801	30D-main	7068.996	0	0.1684	0.442	4	1	0.0471	0.0779	0.129	0.0607	0.249	1.02
			90D-main	7575.456	0	0.0341	0.847	5	0						
			180D-main	6815.121	0	0.0505	0.0906	5	0						
			270D-main	7153.813	0	0.1378	0.716	4	1						
			360D-main	7411.428	0	0.0612	0.0863	5	0						
		43490501	28D-main	1657.661	0	0.4071	0.704	4	0	0.476	1.13	2.68			
			56D-main	1948.489	752.0645	1.7075	0.147	4	0						
			98D-main	1751.79	777.3403	2.2177	0.747	4	0						
		00074299	60D-main	2760.813	981.2055	0.6804	0.81	4	0	0.0271	0.175	1.14			
			90Dmain	2421.826	0	0.0459	0.808	4	0						
	M	41853801	30D-main	8226.059	0	0.0773	0.214	5	0	0.0595	0.0703	0.083	0.0525	0.303	1.75
			90D-main	8423.415	0	0.0809	0.431	5	0						
			180D-main	6952.402	0	0.0616	0.264	5	0						
			270D-main	5830.079	0	0.0735	0.567	5	0						
			360D-main	7016.751	0	0.0622	0.757	5	0						
		43490501	28D-main	1803.999	624.6239	2.7351	0.786	4	0	1.29	1.76	2.39			
			56D-main	1718.906	806.0729	1.8619	0.739	4	0						
			98D-main	1731.205	0	1.3954	0.185	3	1						
		00074299	60D-main	2708.128	1397.578	1.133	0.971	4	0	0.016	0.185	2.14			
			90Dmain	1912.399	0	0.0331	0.729	4	0						
Plasma	F	41853801	30D-main	1530.479	289.2407	0.7698	0.389	5	0	0.535	0.796	1.18	0.47	0.638	0.867
			90D-main	2298.363	482.3706	0.9359	0.339	5	0						
			180D-main	2677.879	57.20462	0.537	0.225	5	0						
			270D-main	2469.771	388.1159	0.7826	0.175	5	0						
			360D-main	2536.284	616.1319	0.8717	0.88	5	0						
		43490501	28D-main	1655.948	0	0.6561	0.988	4	0	0.665	0.734	0.81			
			56D-main	2363.554	0	0.7473	0.409	4	0						
			98D-main	2753.307	0	0.7807	0.65	4	0						
		00074299	30D-main	2597.093	964.4877	0.3646	0.103	4	0	0.246	0.381	0.591			
			60D-main	2708.023	929.1068	0.3396	0.97	4	0						
			90Dmain	2977.949	756.8016	0.3992	0.241	4	0						

Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency
Plasma (con't)	M	41853801	30D-main	374.9871	149.9925	0.8728	0.223	5	0	0.652	1.08	1.78	0.0591	0.275	1.28
			90D-main	470.8639	159.2061	0.8239	0.111	5	0						
			180D-main	557.0498	209.4905	1.2001	0.478	5	0						
			270D-main	550.4859	226.7451	1.51	0.352	5	0						
			360D-main	661.8549	174.4892	0.8715	0.362	5	0						
		43490501	28D-main	467.4461	0	0.4593	0.693	4	0	0.39	0.437	0.489			
			56D-main	472.429	0	0.4382	0.233	4	0						
			98D-main	476.3506	0	0.4	0.721	4	0						
		00074299	60D-main	1462.881	1025.029	0.2974	0.696	4	0	0.0172	0.0392	0.0891			
			90Dmain	1202.18	0	0.0365	0.149	4	0						

Methyl Parathion Figure 1. - Potency Versus Duration of Exposure Graphs

	BRAIN	PLASMA	RBC
F			
M			

Methyl Parathion Figure 2. - Brain Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



Methyl Parathion Figure 3. - Brain Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure

















Methyl Parathion Figure 4. - Plasma Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



Methyl Parathion Figure 5. - Plasma Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



Methyl Parathion Figure 6. - RBC Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



Methyl Parathion Figure 7. - RBC Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



Mevinphos

Mevinphos Table 1. - Toxicology Profile Table

Mevinphos						
MRID #	Guideline No.	Study Type	HED Doc. No.	Dose	Guideline/ Nonguideline	Species/ Strain
42588501	82-1 (870.3100)	90-Day Subchronic Oral Toxicity Study–Rats	015801	0/0, 0.01/0.05, 0.05/0.50, 0.50/1, 0.75/1 mg/kg/day (females/males)	Guideline	Rat/ Crl:CD BR(SD)
45099101	82-7	Subchronic (13 Week) Neurotoxicity Study of Mevinphos –Rats	014518	0/0, 0.03/0.03, 0.35/0.35, 0.60/0.70 mg/kg/day (females/males)	Guideline	Rat/ SD Crl:CD BR
43088601	83-5 (870.4300)	2-Year Chronic Toxicity/Oncogenicity Study of Mevinphos–Rats	In review	MRID deleted because female controls died prior to termination	In review	Rat/ Crl:CD BR(SD)

Mevinphos Table 2. - Results of Dose-Response Analysis: Exponential Parameter Estimates for Oral Route of Exposure

Mevinphos															
Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency
Brain	F	42588501	91D-whole	12.30561	0	1.558593	0.007	4	1	1.46	1.56	1.66	1.46	1.56	1.66
		43088601	MRID deleted because female controls died prior to termination.												
	M	42588501	91D-whole	12.00822	0	1.135227	0.029	3	1	0.95	1.14	1.36	0.95	1.14	1.36
		43088601	MRID deleted because female controls died prior to termination.												
RBC	F	42588501	49D-main	7800.224	0	0.1473235	0.673	5	0	0.114	0.176	0.273	0.0988	0.602	3.67
			91D-main	7351.465	0	0.2062003	0.701	5	0						
		45099101	21D- main	1796.313	0	0.9198221	0.0685	4	0	0.897	2.41	6.47			
			49D-main	1897.225	770.388	4.132715	0.603	4	0						
			91D-main	2076.09	1002.69	6.198667	0.412	4	0						
		43088601	MRID deleted because female controls died prior to termination.												
	M	42588501	49D-main	7053.495	0	0.0692517	0.0608	5	0	0.0603	0.0984	0.161	0.0527	0.46	4.01
			91D-main	8579.318	0	0.102782	0.00219	4	0						
		45099101	21D- main	1968.78	0	1.338713	0.952	3	1	1.1	2.24	4.56			
			49D-main	1892.781	187.969	1.428239	0.599	4	0						
			91D-main	2289.234	812.573	4.155042	0.592	4	0						
		43088601	MRID deleted because female controls died prior to termination.												
Plasma	F	42588501	49D-main	2374.548	164.866	1.904858	0.186	5	0	1.75	2.62	3.92	1.81	2.68	3.96
			91D-main	2919.698	384.448	2.937777	0.324	5	0						
		45099101	21D-main	1641.571	792.475	21.32133	0.309	4	0	0.752	3.86	19.8			
			49D-main	1771.646	878.785	3.286503	0.628	4	0						
			91D-main	2489.668	0	1.273627	0.915	4	0						
		43088601	MRID deleted because female controls died prior to termination.												
	M	42588501	49D-main	537.4627	267.792	5.711482	0.641	5	0	2.23	3.55	5.64	2.21	3.46	5.4
			91D-main	522.0296	202.095	2.88174	0.429	4	0						
		45099101	21D-main	429.1258	0	1.150297	0.902	3	1	0.432	2.4	13.3			
			49D-main	400.3671	0	0.6584257	0.554	4	0						
			91D-main	405.9683	258.473	25.18151	0.25	4	0						
		43088601	MRID deleted because female controls died prior to termination.												

Mevinphos Figure 1. - Potency Versus Duration of Exposure Graphs

	BRAIN	PLASMA	RBC
F			
M			

Mevinphos Figure 2. - Brain Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure















Mevinphos Figure 3. - Brain Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure















Mevinphos Figure 4. - Plasma Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



Mevinphos Figure 5. - Plasma Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



Mevinphos Figure 6. - RBC Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



Mevinphos Figure 7. - RBC Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



Naled

Naled Table 1. - Toxicology Profile Table

Naled						
MRID #	Guideline No.	Study Type	HED Doc. No.	Dose	Guideline/ Nonguideline	Species/ Strain
45222001	82-2 (870.3200)	28-Day Dermal Toxicity Study--Rats (2000)	0144336	0, 5, 10, 40 mg/kg/day	Guideline	Rat/ Crl:CD (SD)BR
00160750	82-2 (870.3200)	28-Day Dermal Toxicity Study–Rats	5774	0, 1, 20, 80 mg/kg/day	Guideline	Rat/ SD
00164224	82-4 (870.3465)	Thirteen-Week Aerosol Inhalation Toxicology	5784	0, 0.2, 1.2, or 6 µg/L	Guideline	Rat/ Fischer-344
00088871	82-1 (870.3100)	Four-Week Subchronic Oral Toxicity Study	1460	0, 0.25, 1, 10, 100 mg/kg/day	Supplementary	Rat/ SD
00141784	83-5 (870.4300)	Chronic Oral Toxicity/Carcinogenicity Study	002997 004128 004521	0, 0.2, 2, 10 mg/kg/day by gavage	Guideline	Rat/ SD
40087201	82-4 (870.3465)	21-Day Inhalation–Rat	004580 006709	0 (air), 4, 8, 16 µg/L (nominal) actual chamber concentration: 0, 3.4, 7.2, 12.1 µg/L	Supplementary	Rat/ Fischer-344

Naled Table 2. - Results of Dose-Response Analysis: Exponential Parameter Estimates for Oral Route of Exposure

Naled															
Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency
Brain	F	00088871	28D-whole	10.8106	2.87833	0.1278615	0.466	5	0	0.117	0.128	0.14	0.109	0.17	0.263
		00141784	714D-whole	7.27375	2.54863	0.2441632	0.549	4	0	0.174	0.244	0.342			
	M	00088871	28D-whole	10.5088	2.68647	0.1282613	0.126	5	0	0.115	0.128	0.144	0.111	0.15	0.21
		00141784	742D-whole	7.17192	2.32693	0.2134431	0.945	4	0	0.144	0.213	0.316			
RBC	F	00141784	175D	2027.89	0	0.00474115	0.186	4	0	0.0607	0.0958	0.151	0.0263	0.05	0.113
			357D	2666.4	0	0.08093208	0.72	3	1						
			539D	2241.87	0	0.07067627	0.0767	3	1						
			714D	2172.36	0	0.1536224	0.975	3	1						
		00088871	28D	1738.09	0	0.03329722	0.385	4	1	0.0256	0.0333	0.0432			
	M	00141784	182D	3064.27	0	0.2083537	0.71	3	1	0.0196	0.0726	0.268	0.0235	0.03	0.0449
			364D	2684.91	0	0.021312	0.23	4	0						
			546D	2257.21	1278.24	0.1140422	0.424	4	0						
			728D	2133.77	976.571	0.07826447	0.0877	4	0						
		00088871	28D	1801.96	0	0.03077814	0.991	4	1	0.022	0.0308	0.043			
Plasma	F	00141784	175D	3338.29	1250.94	0.3037001	0.134	4	0	0.174	0.241	0.335	0.0867	0.16	0.282
			357D	3027.68	0	0.1632189	0.0493	3	1						
			539D	2781.57	1038.93	0.3649978	0.564	4	0						
			714D	2378.72	0	0.2167434	0.012	3	1						
		00088871	28D	1878.53	495.459	0.1031324	0.499	5	0	0.0782	0.103	0.136			
	M	00141784	182D	677.843	292.599	0.4069834	0.494	4	0	0.373	0.503	0.679	0.0261	0.15	0.81
			364D	1007.63	407.822	0.6268904	0.475	4	0						
			546D	1132.68	420.846	0.462995	0.114	4	0						
			728D	1168.31	465.599	0.4108957	0.368	4	0						
		00088871	28D	475.051	0	0.04223011	0.598	4	1	0.0324	0.0422	0.0551			

Naled Figure 1. - Potency Versus Duration of Exposure Graphs

	BRAIN	PLASMA	RBC
F			
M			

Naled Figure 2. - Brain Female Results of Dose-Response Analysis: Dose-Reponse Curves for Oral Route of Exposure



Naled Figure 3. - Brain Male Results of Dose-Response Analysis: Dose-Reponse Curves for Oral Route of Exposure



Naled Figure 4. - Plasma Female Results of Dose-Response Analysis: Dose-Reponse Curves for Oral Route of Exposure



Naled Figure 5. - Plasma Male Results of Dose-Response Analysis: Dose-Reponse Curves for Oral Route of Exposure



Naled Figure 6. - RBC Female Results of Dose-Response Analysis: Dose-Reponse Curves for Oral Route of Exposure



Naled Figure 7. - RBC Male Results of Dose-Response Analysis: Dose-Reponse Curves for Oral Route of Exposure



Oxydemetonmethyl Table 1. - Toxicology Profile Table

Oxydemeton Methyl						
MRID #	Guideline No.	Study Type	HED Doc. No.	Dose	Guideline/ Nonguideline	Species/ Strain
00151806	83-5 870.4300	Chronic Toxicity/oncogenicity Study–Rat	005174 005752 009544	0/0, 0.06/0.05, 0.62/0.49, 6.92/5.84 mg/kg/day (females/males)	Guideline	Rat/ Fischer
00143351	82-1 870.3100	Subchronic Toxicity–Rat	005752	0/0, 0.09/0.08, 0.93/0.75, 13.22/8.25 mg/kg/day (females/males)	Supplementary	Rat/ SPF
41834002		Special NTP Study	012221	0, 0.15, 0.45 or 2.5 mg/kg/day a.i. (males only)	Nonguideline	Rat/ Sprague Dawley
44189501	82-7 870.6200	Subchronic Neurotoxicity–Rat	012212	0, 0.005, 0.02, 0.05, 0.50, 4 mg/kg/day	Guideline	Rat/ Sprague Dawley
44141301		13-week Cholinesterase Study–Rat	012216	0, 0.005, 0.02, 0.05, 0.50, 4 mg/kg/day	Nonguideline	Rat/ Sprague Dawley

Oxydemetonmethyl Table 2. - Results of Dose-Response Analysis: Exponential Parameter Estimates for Oral Route of Exposure

Oxydemeton Methyl														
Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency
Brain	F	00143351	90D-whole	1.970201	0	1.331147	0.0000974	3	1	1.18	1.33	1.5	1.4	1.69	2.04
		151806	810D-whole	12.48674	1.99968	1.440656	0.604	4	0	1.3	1.44	1.6			
		44141301	28D-whole	10.3393	2.286858	2.028372	0.313	6	0	1.94	2.03	2.13			
			56D-whole	9.360266	2.077204	2.018243	0.662	6	0						
			91D-whole	9.81174	2.097718	2.064113	0.759	6	0						
		44189501	28D-whole	10.3469	2.28681	2.029197	0.178	6	0	1.95	2.03	2.12			
			56D-whole	9.360266	2.077204	2.018243	0.596	6	0						
			91D-whole	9.81174	2.097718	2.064113	0.706	6	0						
	M	143351	90D-whole	1.219717	0	0.555742	0.15	3	1	0.429	0.556	0.721	1.02	1.58	2.45
		151806	30D-whole	12.65844	1.4998	1.657448	0.00133	4	0	1.61	1.8	2.02			
			810D-whole	12.08189	1.699905	1.947044	0.931	4	0						
		41834002	93D-whole	12.45683	2.623193	1.930375	0.106	4	0	1.8	1.93	2.07			
		44141301	28D-whole	10.19361	2.300063	2.262649	0.625	6	0	2.08	2.18	2.28			
			56D-whole	9.26511	2.098874	2.133611	0.247	6	0						
			91D-whole	9.640871	2.118562	2.096977	0.935	6	0						
		44189501	28D-whole	10.19361	2.300063	2.262649	0.555	6	0	2.09	2.18	2.27			
			56D-whole	9.26511	2.098874	2.133611	0.177	6	0						
			91D-whole	9.640871	2.118562	2.096977	0.918	6	0						
RBC	F	00143351	28D-main	3077.527	0	0.288233	0.521	3	1	0.228	0.261	0.298	0.251	0.448	0.8
			90D-main	2617.718	0	0.255605	0.00305	3	1						
		151806	210D-main	1624.055	0	0.28886	0.538	3	0	0.209	0.667	2.12			
			360D-main	1460	289.9991	2.041394	Insufficient degrees of freedom to compute a GOF test	3	0						
			540D-main	1120.807	0	0.150607	0.000001	3	0						
			810D-main	1435.675	209.8838	2.205995	0.194	4	0						
		44189501	28d-main	2038.755	0	0.433055	0.693	5	1	0.54	0.678	0.85			
			56D-main	2344.509	0	0.745159	0.878	5	1						
			91D-main	1986.365	0	0.783842	0.494	5	1						

Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency
RBC (con't)	M	143351	28D-main	2967.352	0	0.426778	0.167	3	1	0.352	0.398	0.449	0.51	0.994	1.94
			90D-main	2634.842	0	0.375239	0.00318	3	1						
		151806	30D-main	1647.894	0	0.6377	0.0000162	3	1	1.24	1.69	2.29			
			180D-main	1602.721	0	2.05553	0.00052	3	1						
			210D-main	1320	249.9648	1.767594	Insufficient degrees of freedom to compute a GOF test	3	0						
			360D-main	1726.995	0	1.889664	0.0185	3	1						
			540D-main	1877.553	259.7432	2.238172	0.00164	4	0						
			720D-main	1441.943	309.7269	1.847156	0.105	4	0						
			810D-main	1462.514	249.9116	2.201196	0.489	4	0						
		41834002	25D-main	2474.998	0	1.113769	0.232	3	1	1.22	2.05	3.45			
			58D-main	2462.293	1160.613	3.253094	0.0243	4	0						
			92D-main	2550.34	1280.681	2.442008	0.185	4	0						
		44189501	28D-main	2026.494	0	0.433364	0.796	5	1	0.409	0.763	1.43			
			56D-main	2131.277	0	0.633448	0.139	5	1						
			91D-main	2151.517	918.1059	1.648448	0.749	6	0						
Plasma	F	143351	28D-main	977.1388	35.51319	0.230895	0.0813	4	0	0.162	0.731	3.29	0.918	1.43	2.23
			90D-main	1539.182	0	2.037537	0.00000295	3	1						
		151806	30D-main	1778.045	249.2337	1.100512	0.823	4	0	0.621	1.02	1.68			
			180D-main	2319.626	91.70877	0.69396	0.178	4	0						
			210D-main	2754.269	209.5123	1.243939	0.439	4	0						
			360D-main	2385.428	176.1528	0.917537	0.633	4	0						
			540D-main	2461.505	199.5909	3.259881	0.213	4	0						
			720D-main	1969.253	0	0.335527	0.4	4	0						
			810D-main	2230	209.724	1.285873	Insufficient degrees of freedom to compute a GOF test	3	0						
		44189501	28D-main	1558.635	392.628	1.348994	0.107	6	0	1.46	1.99	2.71			
			56D-main	2141.665	513.4299	2.591007	0.15	6	0						
			91D-main	2184.728	549.4514	1.796132	0.684	6	0						

Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency
Plasma (con't)	M	143351	28D-main	481.2344	0	0.251662	0.0553	4	0	0.243	0.252	0.261	0.421	0.892	1.89
			90D-main	479.4599	275.9502	0.473733	0.43	4	0						
		151806	30D-main	423.9429	0	0.143717	0.0000587	3	1	0.815	1.13	1.57			
			180D-main	649.8545	158.2672	0.970541	0.0807	4	0						
			210D-main	783.8245	129.705	1.357291	0.047	4	0						
			360D-main	709.1758	66.65997	0.900578	0.98	4	0						
			540D-main	829.6335	122.1155	0.769864	0.302	4	0						
			720D-main	1335.162	119.8381	1.516956	0.493	4	0						
			810D-main	1732.857	160.0101	2.076774	0.71	4	0						
		41834002	25D-main	391.9147	115.757	1.659662	0.504	4	0	1.07	1.5	2.11			
			58D-main	376.6983	91.63535	1.4216	0.0867	4	0						
			92D-main	377.4309	98.4559	1.022847	0.434	4	0						
		44189501	28D-main	322.8097	151.6727	1.843453	0.174	6	0	1.14	1.57	2.15			
			56D-main	293.3594	140.1592	1.207211	0.575	6	0						
			91D-main	295.6208	151.2712	1.537914	0.402	6	0						

Oxydemetonmethyl Figure 1. - Potency Versus Duration of Exposure Graphs

	BRAIN	PLASMA	RBC
F			
M			

Oxydemetonmethyl Figure 2. - Brain Female Results of Dose-Response Analysis: Dose-Reponse Curves for Oral Route of Exposure



Oxydemetonmethyl Figure 3. - Brain Male Results of Dose-Response Analysis: Dose-Reponse Curves for Oral Route of Exposure



Oxydemetonmethyl Figure 4. - Plasma Female Results of Dose-Response Analysis: Dose-Reponse Curves for Oral Route of Exposure



Oxydemetonmethyl Figure 5. - Plasma Male Results of Dose-Response Analysis: Dose-Reponse Curves for Oral Route of Exposure





Oxydemetonmethyl Figure 6. - RBC Female Results of Dose-Response Analysis: Dose-Reponse Curves for Oral Route of Exposure



Oxydemetonmethyl Figure 7. - RBC Male Results of Dose-Response Analysis: Dose-Reponse Curves for Oral Route of Exposure



Phorate

Phorate Table 1. - Toxicology Profile Table

Phorate						
MRID #	Guideline No.	Study Type	HED Doc. No.	Dose	Guideline/ Nonguideline	Species/ Strain
00125233	83-5 (870.4300)	2-Year Feeding/Oncogenicity–Rats	013731	0, 0.05, 0.15, 0.30 mg/kg/day	Guideline	CRL:COBS CD (SD)BR
44895302	82-7 (870.6200)	13-Week Dietary Neurotoxicity Study	13767	0/0, 0.04/0.04, 0.08/0.07, 0.33/0.54 mg/kg/day (females/males)	Guideline	Rat/ Sprague Dawley
44895301	82-1 (870.3100)	Rangefinding Dietary Neurotoxicity	137767	0/0, 0.10/0.09, 0.20/0.19, 0.52/0.69 mg/kg/day (females/males)	Supplementary	Not Stated

Phorate Table 2. - Results of Dose-Response Analysis: Exponential Parameter Estimates for Oral Route of Exposure

Phorate														
Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency
Brain	F	00125233	720D-whole	2744.38	0	2.24	0.187	3	0	1.22	2.24	4.13	0.26	0.71	1.99
		44895301	21D-whole	19355.92	0	0.34	0.892	3	1	0.20	0.34	0.57			
		44895302	91D-whole	17896.51	0	0.42	0.378	3	1	0.12	0.42	1.51			
			91D-whole duplicate	20538.86	0	3.37	0.040	4	0	2.71	3.37	4.19	2.71	3.37	4.19
	M	44895301	21D-whole	19003.59	0	0.01	0.676	3	1	6.18E-15	0.01	1.65E+10	1.36	1.56	1.79
		44895302	91D-whole	18478.54	0	1.56	0.268	4	0	1.36	1.56	1.79			
			91D-whole duplicate	18619.35	0	1.19	0.346	4	0	0.96	1.19	1.47	0.96	1.19	1.47
RBC	F	44895301	21D-main	1222.64	0	2.42	0.020	3	1	1.33	2.42	4.39	3.88	4.49	5.2
		44895302	91D-duplicate	1920.56	0	5.17	0.055	4	0	4.02	4.67	5.43			
			28D-main	1394.97	0	5.02	0.823	4	0						
			56D-main	1226.00	0	1.45	0.195	3	1						
			91D-main	1950.41	0	4.40	0.019	4	0						
	M	44895301	21D-main	1362.20	0	3.13	0.534	4	0	2.53	3.13	3.87	2.69	3.02	3.39
		44895302	91D-duplicate	1802.47	0	2.51	0.736	4	0	2.59	2.97	3.42			
			28D-main	1289.66	0	3.51	0.956	4	0						
			56D-main	1169.86	0	0.23	0.593	3	1						
			91D-main	1636.96	0	2.96	0.347	4	0						
Plasma	F	00125233	90D-main	1565.89	0	3.06	0.429	4	0	2.83	3.49	4.31	3.07	3.39	3.75
			120D-main	2171.14	0	4.01	0.500	4	0						
			720D-main	1968.62	0	3.36	0.842	4	0						
		44895301	21D-main	1716.05	0	3.02	0.185	4	0	2.36	3.02	3.85			
		44895302	91D-duplicate	2915.27	0	4.45	0.105	4	0	3.05	3.46	3.93			
			28D-main	1361.02	0	2.94	0.016	4	0						
			56D-main	2143.70	0	3.53	0.008	4	0						
			91D-main	2484.12	0	3.27	0.015	4	0						
	M	00125233	360D-main	739.00	0	1.88	0.536	4	0	1.13	3.40	10.30	0.45	0.958	2.02
			720D-main	1550.95	590.78383	11.55	0.369	4	0						
		44895301	21D-main	544.19	0	0.50	0.038	4	0	0.31	0.50	0.82			
		44895302	91D-duplicate	584.27	255.00	2.70	0.594	4	0	0.55	0.86	1.34			
			28D-main	512.51	0	0.84	0.339	4	0						
			56D-main	577.83	143.83939	1.92	0.571	4	0						
			91D-main	570.24	143.66215	1.54	0.196	4	0						

Phorate Figure 1. - Potency Versus Duration of Exposure Graphs

	BRAIN	PLASMA	RBC
F			
M			

Phorate Figure 2. - Brain Female Results of Dose-Response Analysis: Dose-Reponse Curves for Oral Route of Exposure









Phorate Figure 3. - Brain Male Results of Dose-Response Analysis: Dose-Reponse Curves for Oral Route of Exposure



Phorate Figure 4. - Plasma Female Results of Dose-Response Analysis: Dose-Reponse Curves for Oral Route of Exposure



Phorate Figure 5. - Plasma Male Results of Dose-Response Analysis: Dose-Reponse Curves for Oral Route of Exposure



Phorate Figure 6. - RBC Female Results of Dose-Response Analysis: Dose-Reponse Curves for Oral Route of Exposure











Phorate Figure 7. - RBC Male Results of Dose-Response Analysis: Dose-Reponse Curves for Oral Route of Exposure











Phosalone

Phosalone Table 1. - Toxicology Profile Table

Phosalone						
MRID #	Guideline No.	Study Type	HED Doc. No.	Dose	Guideline/ Nonguideline	Species/ Strain
44801002	83-5 (870.4300)	Combined Chronic/Oncogenicity–Rats	13753	0/0, 0.28/0.24, 2.87/2.19, 46.50/31.80 mg/kg/day (females/males)	Guideline	Rat/ Sprague Dawley
44852504	82-7 (870.6200)	13-Week Neurotoxicity Feeding –Rats	13753	0/0, 5/4.6, 14.70/13.80, 61.90/55.80 mg/kg/day (females/males)	Guideline	Rat/ Crl:CDBR

Phosalone Table 2. - Results of Dose-Response Analysis: Exponential Parameter Estimates for Oral Route of Exposure

Phosalone														
Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency
Brain	F	44801002	728D-whole	5.92	0	0.03	3.51E-05	4	0	0.02	0.03	0.03	0.02	0.02	0.03
		44852504	91D-whole	7.36	0	0.01	0.110	3	1	0.01	0.01	0.03			
			28D-whole duplicate	7.65	0	0.03	0.078	4	0	0.02	0.03	0.03	0.02	0.03	0.03
			56D-whole duplicate	5.54	0	0.02	0.373	4	0						
	M	44801002	728D-whole	5.16	0	0.04	0.992	4	0	0.04	0.04	0.05	0.02	0.03	0.05
		44852504	91D-whole	8.44	0	0.02	0.386	4	0	0.02	0.02	0.02			
			28D-whole duplicate	7.34	0	0.01	0.865	4	0	0.02	0.03	0.06	0.02	0.03	0.06
			56D-whole duplicate	6.88	1.61	0.04	0.102	4	0						
RBC	F	44801002	91D-main	1233.90	0	0.15	0.603	3	0	0.05	0.13	0.31	0.02	0.05	0.14
			182D-main	1434.85	0	0.17	0.228	3	0						
			364D-main	1300.63	0	0.24	0.682	3	0						
			546D-main	1528.99	0	0.02	0.854	3	0						
			728D-main	2391.56	519.95	0.29	0.896	4	0						
		44852504	28D-duplicate	3351.24	0	0.03	0.186	3	1	0.02	0.03	0.04			
			56D-duplicate	2874.57	0	0.04	0.347	3	1						
			91D-main	2534.44	0	0.03	0.111	3	1						
	M	44801002	91D-main	1211.89	0	0.12	0.873	3	0	0.04	0.11	0.26	0.04	0.09	0.20
			182D-main	1372.71	0	0.20	0.244	3	0						
			546D-main	1705.37	0	0.23	0.824	3	0						
			728D-main	1685.68	0	0.03	0.885	4	0						
		44852504	28D-duplicate	2481.63	1976.14	0.05	0.705	4	0	0.00	0.03	0.22			
			56D-duplicate	2229.24	0	4.70E-03	0.140	4	0						
			91D-main	2723.58	1073.23	0.14	0.473	4	0						
Plasma	F	44801002	91D-main	1487.17	369.80	0.20	0.309	4	0	0.13	0.18	0.23	0.07	0.12	0.20
			182D-main	1461.66	319.20	0.16	0.356	4	0						
			364D-main	1314.39	409.56	0.17	0.714	4	0						
			546D-main	1416.57	479.61	0.17	0.965	4	0						
			728D-main	1225.91	439.61	0.17	0.439	4	0						
		44852504	28D-duplicate	885.53	98.31	0.07	0.127	4	0	0.07	0.08	0.09			
			56D-duplicate	1161.50	118.80	0.07	0.077	4	0						
			91D-main	1128.80	124.45	0.09	0.783	4	0						
	M	44801002	91D-main	414.34	0	0.02	0.069	4	0	0.02	0.04	0.09	0.03	0.04	0.06
			182D-main	404.61	149.13	0.06	0.055	4	0						
			364D-main	484.66	0	0.02	0.338	4	0						
			546D-main	660.74	266.90	0.07	0.277	4	0						
			728D-main	795.43	258.14	0.18	0.771	4	0						
		44852504	28D-duplicate	367.63	44.87	0.04	0.228	4	0	0.03	0.04	0.06			
			56D-duplicate	379.22	59.31	0.04	0.060	4	0						
			91D-main	380.73	71.13	0.06	0.371	4	0						

Phosalone Figure 1. - Potency Versus Duration of Exposure Graphs

	BRAIN	PLASMA	RBC
F			
M			

Phosalone Figure 2. - Brain Female Results of Dose-Response Analysis: Dose-Reponse Curves for Oral Route of Exposure



Phosalone Figure 3. - Brain Male Results of Dose-Response Analysis: Dose-Reponse Curves for Oral Route of Exposure



Phosalone Figure 4. - Plasma Female Results of Dose-Response Analysis: Dose-Reponse Curves for Oral Route of Exposure



Phosalone Figure 5. - Plasma Male Results of Dose-Response Analysis: Dose-Reponse Curves for Oral Route of Exposure



Phosalone Figure 6. - RBC Female Results of Dose-Response Analysis: Dose-Reponse Curves for Oral Route of Exposure



Phosalone Figure 7. - RBC Male Results of Dose-Response Analysis: Dose-Reponse Curves for Oral Route of Exposure



Phosmet

Phosmet Table 1. - Toxicology Profile Table

Phosmet						
MRID #	Guideline No.	Study Type	HED Doc. No.	Dose	Guideline/ Nonguideline	Species/ Strain
41916401	83-5 (870.4300)	Chronic/Oncogenicity–Rat	9828 10756	0/0, 1.1/1.1, 2.1/1.8, 10.9/9.4, 27.1/22.7 mg/kg/day (females/males)	Guideline	Rat/ Sprague Dawley
44811801	82-7 (870.6200)	Subchronic Neurotoxicity –Rat	13522	0/0, 1.9/1.7, 3.9/3.4, 12.1/10.4 mg/kg/day (females/males)	Guideline	Rat/ Sprague Dawley

Phosmet Table 2. - Results of Dose-Response Analysis: Exponential Parameter Estimates for Oral Route of Exposure

Phosmet															
Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency
Brain	F	41916401	360D-whole	1.43	0.68	0.08	0.169	5	0	0.02	0.04	0.09	0.08	0.09	0.10
			720D-whole	1.83	0	0.02	0.080	4	0						
		44811801	21D-whole	25.48	0	0.08	0.062	4	0	0.08	0.09	0.10			
			49D-whole	22.96	0	0.10	0.111	4	0						
	M	41916401	360D-whole	1.60	0.84	0.07	0.489	5	0	1.51E-02	0.02	0.03	0.02	0.03	0.07
			720D-whole	1.94	0	0.02	0.002	4	0						
		44811801	21D-whole	23.26	0	0.03	0.217	3	1	0.04	0.05	0.07			
			49D-whole	21.17	0	0.06	0.468	4	0						
RBC	F	41916401	180D-main	1570.72	111.08	0.17	0.878	5	0	0.11	0.15	0.20	0.12	0.14	0.18
			360D-main	1431.12	247.06	0.25	0.051	5	0						
			540D-main	1538.87	0	0.13	0.513	4	0						
			720D-main	1705.62	0	0.11	0.650	4	0						
		44811801	21D-main	2456.37	0	0.09	0.067	4	0	0.09	0.14	0.20			
			49D-main	2293.16	0	0.18	0.211	4	0						
			91D-main	1600.95	0	0.20	0.046	3	0						
	M	41916401	180D-main	1802.68	435.50	0.27	0.277	5	0	0.12	0.16	0.22	0.10	0.12	0.15
			360D-main	1414.81	293.81	0.20	0.250	5	0						
			540D-main	1476.20	0	0.13	0.764	4	0						
			720D-main	1842.83	0	0.11	0.954	4	0						
		44811801	21D-main	3714.13	0	0.10	0.807	4	0	0.10	0.11	0.12			
			49D-main	3411.72	0	0.11	0.110	4	0						
			91D-main	3622.08	0	0.11	0.648	4	0						
Plasma	F	41916401	180D-main	3561.92	608.31	0.08	0.318	5	0	0.06	0.10	0.15	0.07	0.11	0.15
			360D-main	2120.27	571.14	0.09	0.990	5	0						
			540D-main	2968.71	1631.87	0.30	0.352	4	0						
			720D-main	2191.85	973.85	0.15	0.318	4	0						
		44811801	21D-main	2676.34	630.86	0.23	0.603	4	0	0.07	0.13	0.25			
			49D-main	2858.53	0	0.08	0.246	4	0						
			91D-main	3129.27	1649.79	0.25	0.215	4	0						
	M	41916401	180D-main	670.11	325.65	0.07	0.870	5	0	0.02	0.10	0.39	0.03	0.04	0.06
			360D-main	707.49	222.21	0.06	0.821	5	0						
			540D-main	1354.78	622.34	0.61	0.945	4	0						
			720D-main	917.14	0	0.02	0.768	4	0						
		44811801	21D-main	559.74	259.99	0.14	0.648	4	0	0.03	0.04	0.06			
			49D-main	539.02	0	0.02	0.238	4	0						
			91D-main	581.86	0	0.04	0.706	4	0						

Phosmet Figure 1. - Potency Versus Duration of Exposure Graphs

	BRAIN	PLASMA	RBC
F			
M			

Phosmet Figure 2. - Brain Female Results of Dose-Response Analysis: Dose-Reponse Curves for Oral Route of Exposure



Phosmet Figure 3. - Brain Male Results of Dose-Response Analysis: Dose-Reponse Curves for Oral Route of Exposure



Phosmet Figure 4. - Plasma Female Results of Dose-Response Analysis: Dose-Reponse Curves for Oral Route of Exposure



Phosmet Figure 5. - Plasma Male Results of Dose-Response Analysis: Dose-Reponse Curves for Oral Route of Exposure



Phosmet Figure 6. - RBC Female Results of Dose-Response Analysis: Dose-Reponse Curves for Oral Route of Exposure



Phosmet Figure 7. - RBC Male Results of Dose-Response Analysis: Dose-Reponse Curves for Oral Route of Exposure



Pirimiphos Methyl

Pirimiphos Methyl Table 1. -Toxicology Profile Table

Pirimiphos Methyl						
MRID #	Guideline No.	Study Type	HED Doc. No.	Dose	Guideline/ Nonguideline	Species/ Strain
00129343	82-1 (870.3100)	Subchronic Feeding–Rat	014067 3582	0, 0.25, 0.40, 0.50, 2.50 mg/kg/day	Guideline	Rat/ Wistar
43608201	82-7 (870.6200)	90-Day Subchronic Neurotoxicity–Rat	12054	0/0, 0.2/0.2, 2.4/2.1, 24.7/21.1 mg/kg/day (females/males)	Guideline	Rat/ Sprague Dawley
92147035	83-5 (870.4300)	Chronic Toxicity/Carcinogenicity–Rat	14067 3582 5105 8819	0, 0.5, 2.5, 15 mg/kg/day	Guideline	Rat/ Wistar

Pirimiphos Methyl Table 2. - Results of Dose Response Analysis: Exp.Parameter Estimates for Oral Route of Exposure

Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency
Brain	F	00129343	28D-whole	34.9768619	0	0.062875	0.49	5	0	0.0396	0.0629	0.0997	0.0213	0.0383	0.069
		92147035	84D-whole	31.5269706	0	0.025156	0.0984	4	0	0.0237	0.0264	0.0294			
			182D-whole	27.096617	0	0.031785	0.555	4	0						
			364D-whole	25.3348149	0	0.026703	0.141	4	0						
			728D-whole	26.2441737	0	0.014819	0.674	4	0						
	M	00129343	28D-whole	31.025261	0	0.034889	0.729	5	0	0.0133	0.0349	0.0915	0.0134	0.0276	0.057
		92147035	84D-whole	31.9112615	0	0.01211	0.518	4	0	0.00686	0.0205	0.0613			
			182D-whole	34.4903698	0	0.105504	0.564	3	1						
			364D-whole	27.3438736	0	0.004982	0.232	4	0						
			728D-whole	27.2603035	0	0.026349	0.15	4	0						
RBC	F	00129343	28D-duplicate	896.931183	0	0.01069	0.747	5	0	0.0153	0.0538	0.189	0.0244	0.034	0.0475
			21D-main	1028.622	0	0.056989	0.592	5	0						
		43608201	21D-main	2042.85	0	0.023471	0.66	4	0	0.0157	0.0384	0.0941			
			49D-main	2038.01773	1061.4575	0.124952	0.704	4	0						
			91D-main	2041.314	1095.141	0.069763	0.874	4	0						
		92147035	28D-main	1220.622	234.546	0.069907	0.604	4	0	0.022	0.032	0.0465			
			42D-main	1387.321	46.59597	0.034112	0.178	4	0						
			56D-main	1272.56064	661.29342	0.129177	0.153	4	0						
			84D-main	1337.159	0	0.027445	0.834	4	0						
			182D-main	1601.378	633.1516	0.072312	0.375	4	0						
			273D-main	1342.44926	663.44631	0.102312	0.638	4	0						
			364D-main	1107.9418	482.70638	0.123893	0.573	4	0						
			455D-main	1229.026	0	0.025725	0.815	4	0						
			546D-main	1107.55006	527.14145	0.10381	0.108	4	0						
			637D-main	1062.071	0	0.03076	0.602	4	0						
			728D-main	1535.151	848.3205	0.081913	0.0914	4	0						
	M	00129343	28D-duplicate	Did not converge to exponential function											
			21D-main												
		43608201	21D-main	2011.5314	1066.0512	0.200097	0.762	4	0	0.0152	0.0401	0.105	0.025	0.0319	0.0407
			49D-main	2008.99	0	0.024133	0.405	4	0						
			91D-main	2085.014	0	0.022725	0.896	4	0						
		92147035	28D-main	1131.64897	924.29321	0.257713	0.673	4	0	0.0244	0.0314	0.0404			
			42D-main	1183.153	0	0.024732	0.706	4	0						
			56D-main	940.713222	0	0.024174	0.755	4	0						
			84D-main	1445.568	657.6992	0.071058	0.0575	4	0						
			182D-main	1495.04442	777.09938	0.117962	0.366	4	0						
			273D-main	1128.163	0	0.03945	0.735	4	0						
			364D-main	1098.816	0	0.014723	0.553	4	0						
			455D-main	1468.241	0	0.011075	0.673	4	0						
			546D-main	992.046165	200.55244	0.056435	0.804	4	0						
			637D-main	1041.76842	0	0.040525	0.571	4	0						
			728D-main	999.966007	608.05587	0.104333	1	4	0						

Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency
Plasma	F	00129343	28D-duplicate	1962.77481	0	0.378925	0.269	5	0	0.289	0.34	0.4	0.36	0.439	0.536
			21D-main	1963.28246	0	0.302913	0.319	5	0						
		43608201	21D-main	1638.23653	274.87407	0.475259	0.0535	4	0	0.441	0.524	0.622			
			49D-main	2052.6792	295.75459	0.497038	0.0541	4	0						
			91D-main	2654.66808	245.63896	0.555562	0.0555	4	0						
		92147035	28D-main	3924.85759	643.42262	0.418858	0.656	4	0	0.432	0.472	0.516			
			42D-main	4202.32742	1101.3352	0.550972	0.548	4	0						
			56D-main	3725.81844	745.01256	0.422022	0.783	4	0						
			84D-main	3601.90221	597.63018	0.509059	0.61	4	0						
			182D-main	4106.89905	665.48846	0.445453	0.856	4	0						
			273D-main	3535.28922	387.34404	0.470515	0.912	4	0						
			364D-main	3804.72484	378.14599	0.377809	0.986	4	0						
			455D-main	2959.83261	339.37786	0.485863	0.16	4	0						
			546D-main	2690.36351	289.36729	0.531734	0.77	4	0						
			637D-main	2539.4945	356.60001	0.419756	0.419	4	0						
			728D-main	3117.09783	597.79541	0.480295	0.86	4	0						
	M	00129343	28D-duplicate	715.954199	0	0.147966	0.25	5	0	0.121	0.146	0.177	0.132	0.157	0.186
			21D-main	607.84981	0	0.142896	0.589	5	0						
		43608201	21D-main	426.024023	210.24304	0.393065	0.0411	4	0	0.157	0.26	0.431			
			49D-main	405.996205	198.68056	0.289956	0.213	4	0						
			91D-main	361.612744	0	0.144549	0.117	3	1						
		92147035	28D-main	693.401682	182.22849	0.070406	0.899	4	0	0.0881	0.15	0.257			
			42D-main	802.499105	109.87584	0.060337	0.407	4	0						
			56D-main	796.112528	316.39498	0.13467	0.887	4	0						
			84D-main	656.530649	0	0.037814	0.663	4	0						
			182D-main	563.246131	227.21322	0.137249	0.363	4	0						
			273D-main	626.052712	228.4314	0.168381	0.129	4	0						
			364D-main	778.133221	209.74078	0.093347	0.188	4	0						
			455D-main	779.357077	131.72923	0.208889	0.584	4	0						
			546D-main	793.399166	256.91138	0.339713	0.633	4	0						
			637D-main	659.744668	267.15147	0.328296	0.992	4	0						
			728D-main	615.708548	183.74125	0.218971	0.719	4	0						

Pirimiphos Methyl Figure 1. - Potency Versus Duration of Exposure Graphs

	BRAIN	PLASMA	RBC
F			
M			

Pirimiphos Methyl Figure 2. - Brain Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



Pirimiphos Methyl Figure 3. - Brain Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



Pirimiphos Methyl Figure 4. - Plasma Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure











Pirimiphos Methyl Figure 5. - Plasma Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure











Pirimiphos Methyl Figure 6. - RBC Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure











Pirimiphos Methyl Figure 7. - RBC Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure











Terbufos

Terbufos Table 1. - Toxicology Profile Table

Terbufos						
MRID #	Guideline No.	Study Type	HED Doc. No.	Dose	Guideline/ Nonguideline	Species/ Strain
00109446	82-1 (870.3100)	Subchronic Toxicity Study–Rat	002377 005612	0/0, 0.01/0.01, 0.02/0.02, 0.05/0.04, 0.095/0.08 mg/kg/day (females/males)	Guideline	Rat/ SD
40089602	83-1 (870.4100)	One-year Dietary Toxicity Study–Rat	006352	0/0, 0.009/0.007, 0.04/0.03, 0.07/0.06 mg/kg/day (females/males)	Guideline	Rat/ CD (SD derived) (COBs)
00049236	83-5 (870.4300)	Combined Chronic Toxicity/Carcinogenicity Study–Rats	004898 003847 (ChE) 001514 005612	0/0, 0.01/0.01, 0.05/0.04, 0.22/0.33 mg/kg/day (females/males)	Guideline	Rat/ Long Evans
44842302	82-7 (870.6200)	Subchronic Neurotoxicity Study–Rat (1999)	013572	0/0, 0.04/0.04, 0.06/0,06, 0.25/0.37 mg/kg/day (females/males)	Guideline	Rat/ Crl:CD(SD)IGS

Terbufos Table 2. - Results of Dose Response Analysis: Exp.Parameter Estimates for Oral Route of Exposure

Terbufos															
Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency
Brain	F	00109446	90D-whole	2.42	0	0.45	0.970	5	0	0.05	0.45	3.77	4.17	4.88 (brain-F-	5.73
		40089602	364D-whole	9.39	0	1.46	0.171	4	0	0.82	1.46	2.58	1.54	2.89 (brain-F-whole)	5.41
		44842302	91D-duplicate whole	20.12	0	4.88	0.003	4	0	4.17	4.88	5.73			
			91D-whole	20.74	0	5.38	1.03E-07	4	0	4.87	5.38	5.94			
		00049236	90D-whole	1.43	0	1.97	0.870	3	1	3.46	3.91	4.41			
			720D-whole	1.56	0	3.96	0.215	4	0						
	M	00109446	90D-whole	2.47	0	0.93	0.298	5	0	0.35	0.93	2.47	2.01	2.3 (brain-M-	2.63
		40089602	364D-whole	9.39	0	1.29	0.069	4	0	0.81	1.29	2.05	1.39	2.05 (brain-M-whole)	3.02
		44842302	91D-duplicate whole	18.72	0	2.30	0.060	4	0	2.01	2.30	2.63			
			91D-whole	19.18	0	2.45	0.051	4	0	2.22	2.45	2.69			
		00049236	90D-whole	1.48	0	2.93	0.156	4	0	2.81	3.04	3.28			
			720D-whole	1.53	0	3.10	0.148	4	0						
RBC	F	00109446	30D-main	14.96	0	0.26	0.067	5	0	0.02	0.24	2.51	0.45	2.01	8.94
			60D-main	14.50	0	0.18	0.489	5	0						
			90D-main	13.80	0	0.23	0.850	5	0						
		40089602	42D-main	5717.12	0	0.10	0.285	4	0	0.12	0.47	1.86			
			91D-main	4762.94	0	1.00	0.776	4	0						
			182D-main	7066.18	0	0.45	0.368	4	0						
			364D-main	7747.49	0	0.44	0.567	4	0						
		44842302	91D-duplicate	1200.84	0	4.03	0.182	3	1	3.03	10.60	37.00			
			28D-main	Did not converge to exponential function											
			56D-main	1395.32	0	3.53	0.312	3	1						
			91D-main	1325.37	0	6.44	0.413	3	1						
		00049236	30D-main	0.29	0	2.63	0.051	4	0	2.73	5.75	12.10			
			90D-main	0.45	0.08	15.57	0.902	4	0						
			180D-main	0.51	0	3.83	0.988	4	0						
			360D-main	0.69	0	2.48	0.360	4	0						
			540D-main	0.51	0.07	5.26	0.867	4	0						
			720D-main	0.43	0.15	20.51	0.994	4	0						
	M	00109446	30D-main	14.11	0	2.10	0.291	3	2	0.23	1.24	6.78	1.17	3.79	12.30
			60D-main	15.44	0	0.42	0.131	5	0						
			90D-main	11.18	0	0.37	0.545	4	1						
		40089602	42D-main	5380.27	0	1.54	0.740	4	0	0.54	0.96	1.72			
			91D-main	6225.73	0	1.29	0.503	4	0						
			182D-main	7109.12	0	0.85	0.832	4	0						
			364D-main	8929.19	0	0.40	0.090	4	0						
		44842302	91D-duplicate	1202.45	0	5.97	0.042	3	1	10.20	12.90	16.40			
			28D-main	1388.05	0	16.15	0.163	4	0						
			56D-main	1382.67	12.33	10.75	0.706	4	0						
			91D-main	1515.13	0	11.85	0.571	4	0						

Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency
RBC (con't)	M (con't)	00049236	30D-main	0.33	0	1.36	0.341	4	0	3.68	9.25	23.30	1.17 (con't)	3.79 (con't)	12.30 (con't)
			90D-main	0.44	0.14	13.85	0.882	4	0						
			180D-main	0.52	0.16	19.71	0.696	4	0						
			360D-main	0.51	0.27	6.77	0.800	4	0						
			540D-main	0.58	0.22	16.90	0.612	4	0						
			720D-main	0.40	0.15	17.94	0.946	4	0						
Plasma	F	00109446	30D-main	1553.30	0	6.56	0.093	5	0	5.62	7.03	8.81	5.50	6.43	7.53
			60D-main	2029.27	0	6.74	0.465	5	0						
			90D-main	2678.78	0	7.65	0.513	5	0						
		40089602	42D-main	1604.96	0	7.48	0.156	4	0	5.34	6.94	9.03			
			91D-main	2215.45	0	7.11	0.038	4	0						
			182D-main	2676.11	0	1.84	0.386	3	1						
			364D-main	2521.26	0	6.12	0.080	4	0						
		44842302	91D-duplicate	3204.49	0	10.20	0.152	4	0	2.25	4.57	9.26			
			28D-main	1323.25	0	2.16	0.953	3	1						
			56D-main	1844.81	0	2.78	0.267	3	1						
			91D-main	2163.71	0	3.25	0.073	3	1						
		00049236	90D-main	1.02	0.25	11.55	0.948	4	0	2.44	3.93	6.32			
			180D-main	1.43	0	4.02	0.237	4	0						
			360D-main	1.46	0	0.64	0.034	3	0						
			540D-main	1.42	0	6.56	0.002	3	1						
			720D-main	1.18	0	2.26	0.069	4	0						
	M	00109446	30D-main	478.13	0	3.49	0.289	5	0	3.17	4.20	5.57	1.43	2.70	5.07
			60D-main	486.54	0	4.42	0.932	5	0						
			90D-main	504.03	0	4.66	0.557	5	0						
		40089602	42D-main	323.75	0	1.27	0.694	4	0	2.31	3.77	6.15			
			91D-main	351.13	0	2.77	0.331	4	0						
			182D-main	409.52	0	4.54	0.510	4	0						
			364D-main	571.43	187.249	9.89	0.887	4	0						
		44842302	91D-duplicate	571.29	0	3.71	0.157	4	0	3.35	3.66	4.00			
			28D-main	477.60	0	0.12	0.341	3	1						
			56D-main	533.10	0	3.63	0.006	4	0						
			91D-main	528.12	0	3.52	0.890	4	0						
		00049236	90D-main	0.48	0	0.89	0.206	4	0	0.47	0.80	1.37			
			180D-main	0.49	0	0.31	0.565	4	0						
			360D-main	0.60	0	1.23	0.056	4	0						
			540D-main	0.70	0.39	5.41	0.140	4	0						
			720D-main	0.65	0	0.75	0.970	4	0						

Terbufos Figure 1. - Potency Versus Duration of Exposure Graphs

	BRAIN	PLASMA	RBC
F			
M			

Terbufos Figure 2. - Brain Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



Terbufos Figure 3. - Brain Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



Terbufos Figure 4. - Plasma Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure











Terbufos Figure 5. - Plasma Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure











Terbufos Figure 6. - RBC Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure













Terbufos Figure 7. - RBC Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure

Tetrachlorvinphos

Tetrachlorvinphos Table 1. - Toxicology Profile Table

Tetrachlorvinphos						
MRID #	Guideline No.	Study Type	HED Doc. No.	Dose	Guideline/ Nonguideline	
41342001	82-2 (870.3200)	21-Day Dermal Toxicity–Rat	7844	0, 10, 100, 1000 mg/kg/day	Guideline	Rat/ Crl:CD-BR SD
43371201	82-1 (870.3100)	Subchronic Feeding–Rat	11295	0, 5, 100, 250 mg/kg/day	Guideline	Rat/ SD
00112525	83-2 (870.4200)	Chronic Feeding–Rat	002607 007181	0, 0.25, 1.25, 6.25, 100 mg/kg/day	Guideline	Rat/ Porton strain derived from Turnstall Lab
42980901	83-2 (870.4200)	Chronic Feeding–Rat	010884 010884 011295	0/0, 7.8/6.1, 79.7/62.1, 159.9/124.9 mg/kg/day (females/males)	Guideline	Rat/ SD

Tetrachlorvinphos Table 2. - Results of Dose Response Analysis: Exp.Parameter Estimates for Oral Route of Exposure

Tetrachlorvinphos														
Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency
Brain	F	112525	728D-whole	0.77	0	6.40E-04	1.26E-06	5	0	4.92E-04	6.40E-04	8.35E-04	5.20E-04	6.71E-04	8.64E-04
		42980901	364D-whole	10.46	8.46	0.02	0.889	4	0	4.54E-04	1.10E-03	2.67E-03			
			728D-whole	12.35	0	1.05E-03	0.215	4	0						
		43371201	91D-whole	14.17	9.21	3.21E-03	0.230	4	0	9.81E-07	3.21E-03	10.50			
	M	00112525	728D-whole	0.80	0	0.02	2.30E-08	3	2	0.01	0.02	0.03	0.01	0.02	0.03
RBC	F	00112525	728D-main	0.92	0	1.96E-03	0.362	5	0	1.80E-03	1.96E-03	2.13E-03	1.52E-03	5.34E-03	1.88E-02
		42980901	175D-main	692.24	0	7.34E-04	0.438	4	0	6.46E-04	3.37E-03	0.02			
			357D-main	839.92	0	1.40E-03	0.452	4	0						
			539D-main	1637.33	1110.17	0.05	0.534	4	0						
			721D-main	1461.09	1168.48	0.05	0.765	4	0						
		43371201	91D-main	1450.33	123.11	0.02	0.910	4	0	0.01	0.02	0.03			
	M	00112525	728D-main	1.05	0	1.29E-03	0.339	5	0	1.13E-03	1.29E-03	1.46E-03	9.79E-04	2.46E-03	6.16E-03
		43371201	91D-main	409.52	0	4.85E-03	0.613	4	0	3.54E-03	4.85E-03	6.64E-03			
Plasma	F	00112525	728D-main	1.82	0	9.07E-03	4.44E-06	5	0	8.71E-03	9.07E-03	9.45E-03	7.74E-03	1.28E-02	2.13E-02
		42980901	175D-main	2498.59	0	2.53E-03	0.479	4	0	4.12E-03	9.78E-03	0.02			
			357D-main	2546.07	822.54	0.02	0.659	4	0						
			539D-main	2554.54	584.22	0.01	0.740	4	0						
			721D-main	2179.06	795.45	0.02	0.175	4	0						
		43371201	91D-main	2723.27	444.50	0.02	0.825	4	0	0.02	0.02	0.03			
	M	00112525	728D-main	0.64	0	3.41E-03	6.32E-05	5	0	2.97E-03	3.41E-03	3.91E-03	3.10E-03	3.51E-03	3.97E-03
		42980901	357D-main	650.11	0	2.69E-03	0.262	4	0	2.78E-03	3.80E-03	5.20E-03			
			539D-main	793.65	0	4.61E-03	0.582	4	0						
			721D-main	978.57	0	3.15E-03	0.112	4	0						
		43371201	91D-main	586.22	282.89	0.01	0.456	4	0	2.77E-03	7.30E-03	0.02			

Tetrachlorvinphos Figure 1. - Potency Versus Duration of Exposure Graphs

BRAIN **PLASMA** **RBC**

F

M

Tetrachlorvinphos Figure 2. - Brain Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure

Tetrachlorvinphos Figure 3. - Brain Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure

Tetrachlorvinphos Figure 4. - Plasma Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure

Tetrachlorvinphos Figure 5. - Plasma Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure

Tetrachlorvinphos Figure 6. - RBC Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure

Tetrachlorvinphos Figure 7. - RBC Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure

Tribufos

Tribufos Table 1. - Toxicology Profile Table

Tribufos						
MRID #	Guideline No.	Study Type	HED Doc. No.	Dose	Guideline/ Nonguideline	Species/ Strain
42335101	83-5 (870.4300)	Chronic Toxicity/Oncogenicity/Neurotoxicity	010119	0/0, 0.2/0.2, 2.3/1.8, 21.1/16.8 mg/kg/day (females/males)	Guideline	Rat/Fischer 344

Tribufos Table 2. - Results of Dose Response Analysis: Exp.Parameter Estimates for Oral Route of Exposure

Tribufos														
Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency
Brain	F	42335101	364D-whole	13.75	0	0.05	0.111	4	0	0.01	0.03	0.08	0.01	0.03	0.08
			721D-whole	12.82	0	0.01	0.388	3	1						
	M	42335101	364D-whole	13.47	0	0.04	0.052	4	0	0.04	0.04	0.04	0.04	0.04	0.04
			721D-whole	12.70	0	0.01	0.220	3	1						
RBC	F	4233510	84D-main	2881.76	0	0.20	0.404	3	1	0.09	0.18	0.34	0.09	0.18	0.34
			175D-main	2808.18	0	0.03	0.056	4	0						
			343D-main	2603.29	0	0.20	0.050	3	1						
			350D-main	2423.93	1060.55	0.37	3.30E-04	4	0						
			539D-main	2581.99	929.18	0.41	0.061	4	0						
			714D-main	2678.53	0	0.15	0.015	3	1						
	M	42335101	84D-main	2972.00	0	0.26	0.001	3	1	0.19	0.28	0.42	0.19	0.28	0.42
			175D-main	3107.30	1100.91	0.12	0.682	4	0						
			343D-main	2783.99	1169.13	0.47	0.271	4	0						
			350D-main	2787.55	1198.43	0.42	0.236	4	0						
			539D-main	2769.25	858.71	0.44	0.466	4	0						
			714D-main	2751.86	0	0.18	0.068	3	1						
Plasma	F	42335101	84D-main	2399.16	449.95	0.57	0.806	4	0	0.53	0.56	0.60	0.53	0.56	0.60
			175D-main	2911.56	510.03	0.60	0.850	4	0						
			343D-main	2734.17	0	0.39	Insufficient degrees of freedom to compute a GOF test	2	1						
			350D-main	3036.77	480.05	0.61	0.844	4	0						
			539D-main	2941.82	609.83	0.55	0.678	4	0						
			714D-main	2384.60	409.86	0.56	0.460	4	0						
	M	42335101	84D-main	519.43	248.75	0.19	0.181	4	0	0.27	0.38	0.55	0.27	0.38	0.55
			175D-main	639.21	308.49	0.33	0.021	4	0						
			343D-main	762.94	245.26	0.28	0.562	4	0						
			350D-main	807.03	329.14	0.38	0.716	4	0						
			539D-main	1024.67	330.87	0.66	0.063	4	0						
			714D-main	1219.42	260.22	0.65	0.312	4	0						

Tribufos Figure 1. - Potency Versus Duration of Exposure Graphs

BRAIN **PLASMA** **RBC**

F

M

Tribufos Figure 2. - Brain Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure

Tribufos Figure 3. -Brain Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure

Tribufos Figure 4. - Plasma Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure

Tribufos Figure 5. - Plasma Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure

Tribufos Figure 6. - RBC Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure

Tribufos Figure 7. - RBC Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure

Trichlorfon

Trichlorfon Table 1. - Toxicology Profile Table

Trichlorfon						
MRID #	Guideline No.	Study Type	HED Doc. No.	Dose	Guideline/ Nonguideline	Species/ Strain
40306901	82-2 (870.3200)	21-Day Dermal Toxicity–Rabbit	6476	0, 100, 300, 1000 mg/kg/day	Guideline	Rabbit
43871701	82-7 (870.6200)	Subchronic Dietary Neurotoxicity–Rat	13967	0/0, 6.9/6.1, 35.4/31.2, 188.7/164.7 mg/kg/day (females/males)	Guideline	Rat/ Fischer 344
00152137	82-4 (870.3465)	21-Day Inhalation–Rat	004509 004915	0 (EtON/PEG), 12.7, 35.4, 103.5 mg/m^3	Guideline	Rat/ SPF Wistar
41056201	83-5 (870.4300)	Combined Chronic Toxicity/ Carcinogenicity–Rat	9626	0/0, 5.8/4.5, 17.4/13.3, 109.2/85.7 mg/kg/day (females/males)	Guideline	Rat/ Fischer 344

Trichlorfon Table 2. - Results of Dose Response Analysis: Exp.Parameter Estimates for Oral Route of Exposure

Trichlorfon															
Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency
Brain	F	43871701	88D-whole	15.05	0	5.54E-03	0.109	4	0	5.27E-03	5.54E-03	5.81E-03	5.27E-03	5.54E-03	5.81E-03
	M	43871701	87D-whole	14.67	0	1.74E-03	0.004	4	0	1.33E-03	1.74E-03	2.28E-03	1.33E-03	1.74E-03	2.28E-03
RBC	F	41056201	98D-main	2819.14	0	4.54E-03	0.335	3	1	1.98E-03	2.61E-03	3.45E-03	2.16E-03	4.57E-03	9.67E-03
			189D-main	2827.02	0	1.82E-03	0.010	4	0						
			364D-main	2734.80	0	3.14E-03	1.25E-05	4	0						
			553D-main	2723.11	0	2.28E-03	0.066	4	0						
			735D-main	2737.29	0	2.12E-03	0.665	4	0						
		43871701	25D-main	1528.28	79.55	0.01	0.966	4	0	7.30E-03	7.72E-03	8.16E-03			
			88D-main	1530.58	0	7.68E-03	0.021	4	0						
	M	41056201	364D-main	2937.21	0	1.45E-03	4.76E-04	4	0	1.04E-03	3.22E-03	0.01	2.59E-03	4.79E-03	8.84E-03
			553D-main	2873.12	0	1.76E-03	1.91E-04	4	0						
			735D-main	2861.94	0	0.01	0.326	3	1						
		43871701	24D-main	1558.10	94.48	0.01	0.329	4	0	2.72E-03	5.64E-03	0.01			
			87D-main	1387.93	0	3.67E-03	0.099	4	0						
Plasma	F	41056201	98D-main	2268.19	0	8.79E-03	0.163	3	1	4.45E-03	5.43E-03	6.63E-03	4.04E-03	0.01	0.02
			189D-main	2751.73	0	4.14E-03	0.314	4	0						
			364D-main	2845.91	0	5.37E-03	1.84E-04	4	0						
			553D-main	2572.88	0	5.42E-03	0.822	4	0						
			735D-main	2530.13	1267.60	0.01	0.238	4	0						
		43871701	25D-main	1921.51	278.96	0.01	0.097	4	0	0.01	0.02	0.03			
			88D-main	2757.98	0	0.03	0.032	3	1						
	M	41056201	364D-main	735.61	0	2.32E-03	0.055	4	0	2.20E-03	2.96E-03	3.98E-03	2.36E-03	4.99E-03	1.06E-02
			553D-main	990.93	0	3.58E-03	1.20E-04	4	0						
			735D-main	1194.99	623.54	0.01	0.417	4	0						
		43871701	24D-main	568.01	0	8.67E-03	0.227	3	1	5.84E-03	8.74E-03	1.31E-02			
			87D-main	592.07	456.85	0.01	0.067	4	0						

Trichlorfon Figure 1. - Potency Versus Duration of Exposure Graphs

BRAIN **PLASMA** **RBC**

F

M

Trichlorfon Figure 2. - Brain Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure

Trichlorfon Figure 3. - Brain Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure

Trichlorfon Figure 4. - Plasma Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure

Trichlorfon Figure 5. - Plasma Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure

Trichlorfon Figure 6. - RBC Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure

Trichlorfon Figure 7. - RBC Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure